

Curriculum Vitae and Bibliography

Yi Lin, MD, PhD

Personal Information

Citizenship: United States of America
Work Address: Mayo Clinic
200 First Street SW
Rochester, MN 55905
Email Address: lin.yi@mayo.edu

Present Academic Rank and Position

Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 07/02/2014 - Present
Full Faculty Privileges in Clinical & Translational Science - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science 02/19/2018 - Present
Consultant (Joint Appointment) - Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 03/21/2018 - Present
Full Faculty Privileges in Immunology - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science 09/28/2018 - Present
Enterprise Leader - Cancer Regenerative Medicine, Biotherapeutics, and Biomanufacturing, Mayo Clinic Comprehensive Cancer Center 07/06/2022 - Present
Professor of Medicine - Mayo Clinic College of Medicine and Science 12/01/2022 - Present

Education

University of Minnesota, Minneapolis, Minnesota - BS, Chemical Engineering 1992 - 1995
University of Minnesota, Minneapolis, Minnesota - Ph.D., Ph.D. Biomedical Engineering 1995 - 2000
University of Minnesota Medical School, Minneapolis, Minnesota 2000 - 2002
Northwestern University Feinberg School of Medicine, Chicago, Illinois - MD 2002 - 2004
Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota - Resident, Department of Internal Medicine, Mayo Clinic 2004 - 2007
Internal Medicine, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota - Resident 06/26/2004 - 06/29/2007
Division of Hospital Internal Medicine, Department of Internal Medicine - Clinician Investigator Fellow 2007 - 2009
Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota - Fellow, Hematology & medical oncology fellowship, Clinical Investigator Program 2007 - 2011
Clinician Investigator, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota - Resident 03/31/2007 - 06/26/2009
Hematology/Oncology, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota - Resident 06/30/2007 - 07/01/2011

Certification

Board Certifications

American Board of Internal Medicine (ABIM)

Internal Medicine 2007 - Present
Hematology 2011 - Present

Medical Oncology 2011 - Present

Licensure

Minnesota 47971 (Medical) 2005 - Present

Honors and Awards

Merit-based travel award - American Society of Hematology 1998 - Present

Internal Medicine Promising Young Research Scholar - University of Minnesota 1999 - Present

Merit-based travel award - American Society of Hematology 2000 - Present

J. Thomas Livermore Award for Medical Student Achievement in Hematology Research - University of Minnesota Twin Cities 2001 - Present

NIH Loan Repayment Program 07/01/2007 - 07/01/2009

AFLAC Scholar-in-training award - American Association for Cancer Research 2008

Scholarship - Pan-Pacific Lymphoma Conference 2009

NIH Loan Repayment Program 07/01/2012 - 07/01/2013

New Investigator Award - Mayo Clinic Department of Medicine , Rochester, Minnesota 10/30/2017 - Present

Previous Professional Positions and Major Appointments

Instructor of Medicine - Mayo Clinic College of Medicine and Science 09/01/2010 - 04/30/2011

Instructor of Oncology - Mayo Clinic College of Medicine and Science 09/01/2010 - 04/30/2011

Assistant Professor of Medicine - Mayo Clinic College of Medicine and Science 05/01/2011 - 04/30/2018

Senior Associate Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 07/02/2011 - 07/01/2014

Associate Professor of Medicine - Mayo Clinic College of Medicine and Science 05/01/2018 - 11/30/2022

Professional Memberships and Societies

Professional Memberships and Services

AABB
Subcommittee Member 03/03/2014 - 03/03/2018

American Association for Cancer Research
Active Member 2007 - Present

American Society of Clinical Oncology
Active Member 2007 - Present

American Society of Hematology
Active Member 2007 - Present

Center for International Blood and Marrow Transplant Research
Member 10/01/2019 - Present

International Myeloma Working Group
Subcommittee Chair 04/01/2019 - Present

International Society of Cellular Therapy
Active Member 2011 - Present
Subcommittee Member 07/01/2015 - 07/01/2018

Society for Immunotherapy of Cancer
Active Member 2011 - Present

Society for Immunotherapy of Cancer (SITC)
Committee Member 12/01/2020 - Present

Study Sections

Leukemia and Lymphoma Society Translational Research Program
Study Section Reviewer 03/01/2018 - 12/31/2021

National Institutes of Health	
National Cancer Institute	
CONC Peer Review Committee	
Invited Reviewer	10/27/2016
Member, Study Section	01/01/2018 - Present

Journal Responsibilities

Journal Other Responsibilities

American Journal of Hematology	
Manuscript Reviewer	2011 - Present
Blood	
Paper Reviewer	07/01/2011 - Present
Blood Advances	
Referee/Reviewer	01/01/2020 - Present
Journal of Immunotherapy	
Referee/Reviewer	01/01/2020 - Present
Leukemia	
Manuscript Reviewer	2011 - Present
Mayo Clinic Proceedings	
Journal Reviewer	07/01/2011 - Present

Education Interests and Accomplishments

Curriculum and Course Development

Chimeric antigen receptor cell therapy (CART) education Created annual education sessions on updates in CART therapy research and clinical care guidelines to RMH inpatient hematology unit RNs. RMH ST94 RN annual education sessions	01/19/2016
Chimeric antigen receptor cell (CART) therapy Created annual education sessions on updates in CART therapy research and clinical care guidelines to RMH inpatient hematology NP/PA. education session on CART care guideline to ST74 NP/PA	05/03/2016
Chimeric antigen receptor cell (CART) therapy education Created annual education sessions on updates in CART therapy research and clinical care guidelines to MCR hematology and medical oncology fellows. MCR hematology and medical oncology fellows education conference	06/01/2016
Chimeric antigen receptor cell therapy Created annual education sessions on updates in CART therapy research and clinical care guidelines to RMH inpatient hematology unit RNs. RMH ST74 annual RN education	02/14/2017
Chimeric antigen receptor cell (CART) therapy Created annual education sessions on updates in CART therapy research and clinical care guidelines to RMH inpatient hematology unit RNs. Annual RN education session for ST73/93.	03/14/2017
Blackboard Competency and Learning Modules for CAR-T Therapy Created modules on patient selection for CAR-T therapy and management of CAR-T therapy on blackboard. The modules are used for onboarding of new trainees and physicians as well as ongoing self-assessment of competency.	05/01/2019
Mayo Clinic CAR-T Symposium Annual symposium on CAR-T therapy for physicians, scientists, trainees, APP, RN, pharmacy, and program administrators	05/21/2020
SITC Clinical Practice Guideline Webinar: Practice Management Pearls for the Treatment of Multiple Myeloma Educational Webinar Development and Presentation SITC Virtual	04/23/2021

Mayo Clinic CAR-T Symposium Annual update on cell therapy in cancer application, including concurrent tracks for physician scientists, program administrators, pharmacists, RN, APP, and lab. Virtual	05/20/2021
CAR-T Cell Therapy Toxicity and Management Educational Webinar Development and Presentation ASTCT Webinar Virtual	08/30/2021
CAR-T Therapy and Renal Considerations Educational Presentation and Curriculum Development Mayo Clinic Onco-Nephrology Symposium Virtual	10/09/2021
Infection Management in CAR-T Therapy Educational Presentation and Curriculum Development Mayo Clinic Infectious Disease Symposium Maui, Hawaii	02/14/2022
Translating Recent Evidence on CAR-T cell Therapies to Real World Management of Lymphoid Malignancies Course Development and Presenter Physician Education Resources (PER) Reflective Case-Based Series Virtual	04/14/2022

Teaching

CAR-T Therapy in Clinic Mayo Clinic Arizona Cancer Center Grand Round Phoenix, Arizona	08/02/2018
Updates on CAR-T Mayo Clinic Department of Medicine Grand Rounds Rochester, Minnesota	05/05/2021
CAR-T Therapy: Building a Robust Clinical Research Program Lecture and Q&A session given during the Mayo Clinic Clinical Research Training Program, which was conducted internationally across multiple regions in China. Mayo Clinic Clinical Research Training Program Rochester, Minnesota	09/10/2021
CAR-T Therapy: Case Study on Programmatic Implementation During the COVID-19 Pandemic Lecture and Q&A session given during the Mayo Clinic Clinical Research Training Program, which was conducted internationally across multiple regions in China. Mayo Clinic Clinical Research Training Program Rochester, Minnesota	09/10/2021

Mentorship

Warad, Deepti (Clinical Fellow) Description: supervised project with immune phenotyping of patients receiving ECP for GVHD. Current Status: SAC in Pediatric Hematology at MCR Outcome: data gathering and data analysis for manuscript preparation.	01/2011 - 01/2013
Chintakuntalawar, Ashish (Hematology/Oncology Fellow) Description: Discussed research projects. Provided career development advice. Current Status: SAC in medical oncology at MCR Outcome:	01/2012 - 01/2013
Elsedawy, Noura (Research Training Fellow) Description: Lab development of CAR-T in myeloma as a Division of Hematology Kurtz Research Fellow Current Status: Resident Training in Internal Medicine Outcome:	01/2012 - 06/2013
Cordes, Stefan (Internal Medicine Resident) Description: supervised research project in my lab with informatics data analysis of immune changes with vaccine therapy trial and ECP treatment for GVHD.	01/2012 - 06/2014

Current Status: Hematology fellow at NIH
Outcome: Provided data for manuscript submission.

Zhang, Zhe (Research Fellow) 01/2012 - 12/2014
Description: Supervised post-doctoral work in tumor mediated myeloid suppression and potential cancer immune therapeutic targets
Current Status: job in pharma industry
Outcome: Published one first author paper

Schaefer, Jordan (Internal Medicine Resident) 01/2013 - 06/2014
Description: Provided research project development advice and career development advice.
Current Status:
Outcome:

Kenderian, Saad (Junior Faculty) 07/2013 - Present
Description: Provide advice and help facilitate transition from Mayo Scholar to staff work and career development plan Assist with translation of lab studies into clinical trials, building translational research program
Current Status: Professor of Hematology; Consultant, Division of Hematology
Outcome: Obtain development funds to support research, build enterprise biobank and translational biomarker study in CAR-T IND development work for the first in-house manufactured CAR-T trial at Mayo Clinic

Paludo, Jonas (Junior Faculty) 07/2016 - Present
Description: Education curriculum development for Cell Therapy Group Research project in remote monitoring technology and application of artificial intelligence and machine learning to improve medical decision making, healthcare resource utilization and patient experience in CAR-T
Current Status: Assistant professor of medicine Senior Associate Consultant, Division of Hematology
Outcome: Education modules implemented for MD provider onboarding and annual CME maintenance in Immune Effector Cell Program at Mayo Clinic, Rochester, MN, Research project with Kite/Gilead on outpatient practice in CART Research project with Mayo Clinic, Connected Care Program on remote monitoring of CAR-T patients Served as mentor for ASH CRTI scholar

Yan, Yiyi (Clinical Fellow) 09/2016 - 06/2017
Description: Provide grantsmanship advice and career development advice
Current Status: hematology and medical oncology fellow at MCR
Outcome: Joining staff in melanoma group at MCR. Planned submission of NIH K award.

Bennani, Nora (Junior Faculty) 07/2017 - Present
Description: Mentor clinical research project on CAR-T in lymphoma Mentor education curriculum development for Cell Therapy Group
Current Status: Assistant professor of medicine
Outcome: oral presentation at ASH annual meeting 2019 on US Lymphoma CART Consortium data of patients with CNS involvement receiving axicabtagene ciloleucel. Co-author publication in JCO 2020 on real world practice data of axicabtagene ciloleucel in the US from the US Lymphoma CART Consortium Mayo site PI on multi-center clinical trial ZUMA-12 testing axicabtagene ciloleucel and 41BB agonist antibody in patients with relapsed, refractory aggressive B-NHL Education curriculum development of clinical cell therapy fellowship for advanced fellows in the Division of Hematology

Goyal, Gaurav (Hematology/Oncology Fellow) 07/2018 - Present
Description: supervised lab research project on studies of monocytes provide career development advice Provide guidance on junior faculty research project
Current Status: Assistant professor University of Alabama, Birmingham
Outcome:

Ruff, Michael (Junior Faculty) 07/2018 - Present
Description: Mentor clinical research of neurotoxicity in CAR-T therapy
Current Status: Assistant professor Senior Associate Consultant, Department of Neurology
Outcome:

<p>Novo, Mattia (Visiting Clinical/Postdoctoral Fellow) Description: Supervised clinical research in CAR-T at Mayo Clinic Current Status: Staff Hematologist at Academic Center in Italy Outcome: Poster presentation at ASH 2019 on prognostic biomarker to predict clinical response with FDA approved CART in lymphoma, On staff as hematology and CART specialist in Italy, published one paper.</p>	07/2018 - 05/2019
<p>Surbhi, Sidana (Hematology/Oncology Fellow) Description: comparing QOL between patients receiving CART and autologous and allogeneic stem cell transplant. Current Status: Assistant professor Stanford University Outcome: ASCO 2019 poster presentation; ASH 2019 oral presentation on QOL in patients receiving CART and BMT.</p>	07/2018 - 07/2019
<p>Yoon, Harry (Junior Faculty) Description: Advice and guidance for first R01 application Current Status: Assistant professor of oncology Consultant, Department of Oncology Outcome: successfully obtained first R01. Received first percentile ranking on the scientific review.</p>	05/2019 - 07/2020
<p>Khurana, Arushi (Hematology Fellow) Description: clinical outcome for CAR-T in lymphoma. Current Status: Hematology advanced lymphoma fellow 2019 - 2020, Hematology advanced clinical cell therapy fellow 2020-2021 Outcome: ASH annual meeting 2020 oral and poster presentations on clinical outcome in CAR-T, ASTCT annual meeting 2021 oral and poster presentation on clinical outcome in CAR-T. Published several manuscripts.</p>	07/2019 - Present
<p>Al Saleh, Abdullah (Hematology/Oncology Fellow) Description: Supervise clinical research in CAR-T Current Status: Advanced Clinical Cell Therapy Fellow Outcome: Poster presentation at ASCO 2020 on prognostic biomarkers of clinical response with FDA approved CAR-T in lymphoma.</p>	07/2019 - 10/2020
<p>Bezerra, Evandro Description: Clinical outcome in CAR-T therapy Current Status: Clinical fellow, Hematology/Oncology Outcome: Proposed multi-center study on outcome of subsequent therapy after CAR-T treatment to the Cellular Immunotherapy Working Committee of the Center for International Bone Marrow Transplant Research. Project was selected by CIBMTR for work, 2022.</p>	09/2019 - Present
<p>Durani, Urshila (Hematology/Oncology Fellow) Description: CART survivorship research while training as chief fellow in Hematology and Oncology. Provide oversight of the project and career development. Current Status: SAC in the Division of Hematology Outcome:</p>	09/2019 - Present
<p>Scheckel, Caleb (Hematology/Oncology Fellow) Description: Healthcare resource utilization in CAR-T Current Status: Clinical fellow Outcome: Proposed multi-center study on health resource utilization of CAR-T to the Cellular Immunotherapy Working Committee of the Center for International Bone Marrow Transplant Research. Project selected for work by CIBMTR, 2021.</p>	09/2019 - Present
<p>Barreto, Jason (Pharmacy Staff) Description: Current Status: Pharmacist at Rochester Methodist Hospital Outcome: Mentored PhD project on PJP prophylaxis in patients with Hodgkin lymphoma Mentored research project on G-CSF use in CAR-T therapy. Project received poster presentation at ASH annual meeting 2020, and oral presentation at ASTCT annual meeting 2021. Received First Place for pharmacy category for best presentation. Publications.</p>	10/2019 - Present
<p>Kankeu Fonkoua, Lionel (Hematology/Oncology Fellow) Description: Provide advice and guidance on cellular immunotherapy clinical trial</p>	03/2020 - Present

conduct and translational research related to the trial provide advice and guidance on SITC research grant application

Current Status: clinical fellow

Outcome: ASCO YIA

Bansal, Radhika (Research Fellow)

10/2020 - Present

Description:

Current Status: Research Fellow

Outcome: Clinical outcome research in CAR-T therapy. ASTCT annual meeting 2021 poster presentations. ASCO annual meeting 2021, 2 poster presentations.

Academic Career Development

Cancer Education Consortium Molecular and Translational Oncology Workshop
Bethesda, DC 2008

American Society of Clinical Oncology/American Association of Cancer Research
Methods in Clinical Research Workshop
Vail, CO 2009

Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other Activities

Mayo Clinic

2030 Novel Therapeutics Team

co-chair, Cancer Cell Therapy

03/02/2020 - Present

Work with multi-disciplinary team to assess current status, areas of growth, and needs to develop cell therapy for cancer in alignment with institutional 2030 Novel Therapeutics plan.

Center for Regenerative Medicine Cellular Biomanufacturing Committee

Co-Chair

01/01/2020 - 06/01/2020

Co-chair the committee to consolidate information on enterprise manufacturing capability and develop a strategic plan to grow manufacturing capability to support cell therapy of cancer.

Department of Education Administration

Mayo Clinic College of Medicine

Mayo Graduate School of Medicine

Department of Immunology

Active Member

2011 - Present

Department of Internal Medicine

Division of Hematology and Oncology

Amyloidosis Interest Group

Active Staff Member

2013 - Present

Active Staff Member

2013 - Present

Department of Laboratory Medicine and Pathology

Division of Experimental Pathology and Laboratory Medicine

Staff Member

05/01/2018 - Present

Mayo Clinic Cancer Center

Active Member

2011 - Present

Chair, Cell Therapy Cross-Disciplinary Group

06/01/2017 - Present

Leader

07/01/2022 - Present

Enterprise Leader of Cancer Regenerative Medicine, Biotherapeutics and Biomanufacturing

Mayo Clinic Center for Regenerative Medicine

Active Staff Member

2011 - Present

Mayo Clinic Myeloma SPORE

Active Member

08/02/2021 - Present

University of Iowa/Mayo Clinic Lymphoma SPORE

Active Staff Member

2011 - Present

Mayo Clinic in Rochester

Center for Regenerative Medicine

Search Committee member 12/01/2020 - 04/30/2021
 member of search committee for the director of Center of Regenerative Medicine

Department of Internal Medicine

Division of Hematology

Cell Therapy Group

Chair 2011 - Present

Hematology Disease Oriented Group

Active Staff Member 2011 - Present

Myeloma, Amyloidosis, Dysproteinemia Disease Oriented Group

Active Staff Member 2011 - Present

Immunology and Immunotherapy

Active Member 2011 - Present

Activities at Other Institutions

CAR-T Working Group

Member 10/02/2017 - Present

Member of CAR-T Working Group to develop education modules and slide deck on CAR-T therapy for medical professionals. The education slide deck is made available through American Society of Transplant and Cell therapy (ASTCT).

International Myeloma Working Group

Chair/Co-Chair 06/01/2019 - Present

Co-Chair of the Myeloma Immunotherapy Working Group at IMWG

iwCART

Scientific faculty committee member 12/03/2018 - Present

member of scientific faculty committee to develop annual iwCART meetings and chair meeting sessions.

U.S. Lymphoma CAR-T Consortium

Steering Committee Member 05/07/2018 - Present

Original founding member and steering committee member of a consortium of 17 CAR-T treatment centers in the U.S. The consortium gathers clinical data to address key clinical questions regarding the use and management of FDA approved CAR-T in standard of care practice.

Presentations Extramural**National or International****Invited**

Blood outgrowth endothelial cells: origin of endothelial progenitor cells and their 2000

potential clinical applications

NHLBI Workshop on Endothelial Cell Phenotype in Heart, Lung and Blood Disease
 District of Columbia

Dealing with myeloid suppressors in cell therapy: the CD14+HLA-DRneg monocyte 2009

and its effect on cellular immunity

International Society for Cellular Therapy Annual Meeting

Immunotherapy session 2013

American Society of Clinical Oncology Annual Meeting

Bispecific antibodies in myeloma 03/2017

International Myeloma Workshop

Delhi, India

BCMA CAR-T Clinical Trials 10/11/2017

iwMyeloma Symposium

Edinburgh, Scotland, United Kingdom

Chimeric antigen receptor T cell therapy program - advancing to the clinic 06/26/2018

Myongji Hospital Cancer Symposium Seoul, South Korea	
Individualized cancer therapy using CAR-T therapy Center for Individualized Medicine Symposium Rochester, Minnesota	09/12/2018
Transforming multiple myeloma care: CAR-T therapy International Society of Hematology annual meeting Vancouver, British Columbia, Canada	09/15/2018
The Role of CAR-T in Myeloma Hong Kong Society of Myeloma Symposium	11/03/2018
Immunotherapeutic intervention into myeloma therapy Lymphoma and Leukemia Society pre-ASH Symposium	11/30/2018
CAR-T Therapy Advances and Challenges Center for Individualized Medicine Symposium Phoenix, Arizona	09/21/2019
CAR-T in Multiple Myeloma Organizing faculty committee, presenter and moderator of the myeloma CART session iwCART San Diego, California	10/12/2019 - 10/13/2019
Who are the candidates for CAR-T cell therapy? LXI SEHH National Congress Valencia, Spain	10/24/2019 - 10/26/2019
Overcoming Resistance to CAR-T Cells 24th International Congress on Hematologic Malignancies Miami Beach, Florida	02/27/2020
Clinical data and trial update: BCMA CAR-T in Myeloma Virtual Presentation iwMyeloma Virtual	09/16/2020
CART Therapy in Aggressive Lymphoma: US Real World Experience Virtual Presentation Hebei Hematology Society Annual Meeting China	10/23/2020
Education for National/International: OncLive Learning Module: Education along the CAR-T Cell Therapy Journey OncLive Virtual	11/11/2020
CAR-T therapy in aggressive lymphoma Chinese Society of Hematology annual congress	11/13/2020
CAR-T Therapy in Myeloma Virtual Presentation OncLive Institutional Perspectives in Cancer: Myeloma	12/17/2020
BCMA CART in myeloma iwMyeloma	03/25/2021
SITC Clinical Practice Guideline Webinar: Practice Management Pearls for the Treatment of Multiple Myeloma Educational Presentation SITC	04/23/2021
Cytokine Release Management in 2021 2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop by International Myeloma Society	05/07/2021

CAR-T Cell Therapy Toxicity and Management Webinar - Education Session ASTCT Webinar Virtual	08/30/2021
CAR-T and Bispecific Antibody: Mechanism of Resistance 18th International Myeloma Workshop Vienna, Austria	09/09/2021
CAR-T Therapy: Building a Robust Clinical Research Program Lecture and Q&A session given during the Mayo Clinic Research Training Program, which was conducted across multiple regions in China Mayo Clinic Research Training Program	09/10/2021
CAR-T Therapy: Case Study on Programmatic Implementation during the COVID-19 Pandemic Lecture and Q&A given during the Mayo Clinic Clinical Research Training Program which was conducted across multiple regions across China. Mayo Clinic Clinical Research Training Program Virtual	09/10/2021
CAR-T Therapy and Renal Considerations Educational Presentation Mayo Clinic Onco-Nephrology Symposium Virtual	10/09/2021
CAR-T in Myeloma Education Session The First Hematology Master Class, Regenerative Medicine, Transplantation, and Cellular Therapy in Hematology: Past, Present, and Future Abu Dhabi, United Arab Emirates	11/05/2021
Current Cancer Therapy Landscape Education Session Mayo Clinic Symposium on Regenerative Medicine and Surgery Scottsdale, Arizona	11/07/2021
CAR-T in Myeloma CAHON (Chinese American Hematologist and Oncologist Network) Virtual 2021 ASH Winter Symposium Virtual	12/18/2021
SITC Webinar: Focus on Cellular Therapies and T Cell Engagers Educational Webinar Development Faculty, Session Moderator, and Talk on Outpatient Management of CAR-T SITC Webinar	12/18/2021
US Real World Experience of CAR-T in Lymphoma Virtual Presentation Tianjin Cancer Association Lymphoma Professional Committee Annual Meeting Virtual	01/22/2022
Infection Management in CAR-T Therapy Educational presentation Mayo Clinic Infectious Disease Symposium Maui, Hawaii	02/14/2022
Idecabtagene Ciloleucel: Current Status iwMyeloma Virtual	03/25/2022
CAR-T Advances in Myeloma iwCART Tampa, Florida	05/01/2022
Latest advances in Immune Therapies: A Focus on CAR-T Cell Therapies Educational presentation	05/14/2022

International Myeloma Foundation Patient and Family Webinar Virtual	
CAR-T Therapy Update Virtual Presentation Beijing Annual Myeloma Summit Beijing, China	05/21/2022
New CAR-T Therapies for Multiple Myeloma Invited Speaker 2022 ASCO Annual Meeting Chicago, Illinois	06/03/2022
CD19 CAR-T Real World Experience in the US China CAR-T Hematology Summit	06/23/2022
Oral	
Circulating endothelial cells are from vessel wall but peripheral BOEC is from a marrow-derived cell. Plenary session American Society of Hematology Annual Meeting Miami Beach, Florida	12/1998
Novel gene therapy approach to hemophilia: use of stably transfected blood outgrowth endothelial cells. American Society of Hematology Annual Meeting San Francisco, California	12/2000
A population of immunosuppressive CD14+ monocytes found in glioblastoma patients inhibit DC differentiation and T cell function. American Association of Cancer Research Annual Meeting San Diego, California	04/2008
A population of immunosuppressive monocytes inhibiting T cell proliferation and dendritic cell differentiation in relapsed non-Hodgkin's lymphoma. American Society of Hematology Annual Meeting San Francisco, California	12/2008
Immuno-suppressive CD14+HLA-DRneg monocytes are increased in aggressive non-Hodgkin's lymphoma and associated with increased arginase I level. American Society of Hematology Annual Meeting New Orleans, Louisiana	12/2009
Matched case control analysis comparing long term survival of multiple myeloma patients who received stem cell transplant with and without idiotype-pulsed dendritic cell vaccine. American Society of Hematology Annual Meeting San Diego, California	12/2011
Human mesenchymal stromal cells protect human cardiomyocytes from primary amyloid light chain induced cytotoxicity. April 2014, Indianapolis, IN. Oral plenary session presentation. International Symposium on Amyloidosis Indianapolis, Indiana	04/2014
Real-world experience with CAR T cell therapy in aggressive NHL European Hematology Association Annual Congress Amsterdam, Netherlands	06/13/2016
Clinical responses with bb2121, a novel anti-BCMA CAR T cell therapy: initial results from a phase 1 multi-center trial in relapsed/refractory multiple myeloma Plenary Session EORTC/NCI/AACR Symposium Munich, Germany	12/2016
First-in-human multicenter study of bb2121 anti-BCMA CAR T cell therapy for	06/22/2017

relapsed/refractory multiple myeloma: updated results European Hematology Association annual congress	
Axicabtagene ciloleucel in patients with refractory aggressive non-Hodgkin lymphoma: primary results of the pivotal trial ZUMA-1 European Hematology Association annual congress	06/23/2017
Efficacy, safety and covariates of outcomes with axicabtagene ciloleucel from ZUMA-1, a pivotal trial in patients with refractory, aggressive non-Hodgkin lymphoma ESGCT annual meeting Berlin, Germany	10/09/2017
Experience with axicabtagene ciloleucel in patients with secondary CNS lymphoma involvement: results from the US Lymphoma CAR-T Consortium Mentored junior faculty on the project and presentation. American Society of Hematology Annual Meeting	12/09/2019
CAR-T therapy in myeloma Co-organizer of the meeting and speaker. Mayo Clinic CAR-T Symposium Rochester, Minnesota	05/07/2020
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase I CRB-401 study. American Society of Hematology annual meeting	12/05/2020
Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive non-Hodgkin lymphoma mentored advanced clinical cell therapy fellow in the project and presentation American Society of Hematology annual meeting	12/07/2020
Cytokine release syndrome in patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel in the phase 1b/2 CARTITUDE-1 Study. American Society of Transplant and Cell Therapy annual meeting	02/09/2021
Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive non-Hodgkin lymphoma mentored project American society of transplant and cell therapy annual meeting	02/09/2021
Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study Oral Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/09/2021
Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL) Oral Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/09/2021
Utility of granulocyte colony stimulating factor in patients receiving chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel mentored project, won first place in best abstract in pharmacy category. American society of transplant and cell therapy annual meeting	02/10/2021
Prophylactic Steroid Use of Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma Oral Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/10/2021
The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel	02/10/2021

Oral Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	
Interim Analysis (IA) of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients (Pts) with High-Risk Large B Cell Lymphoma (LBCL) Oral Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/12/2021
Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma treated with ciltacabtagene autoleucel in the Phase 1b/2 CARTITUDE-1 Study COMy - 7th World Congress on Controversies in Multiple Myeloma (COMy)	05/07/2021
Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. Oral Abstract 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Oral Abstract 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
Idecabtagene Vicleucel, a BCMA-directed CAR T Cell Therapy: Phase 1 CRB-401 Update Oral Presentation Japanese Society of Hematology Annual Meeting	09/23/2021
BASECAMP-1: An Observation Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for future CAR-T Cell Therapy SITC Annual Meeting Bethesda, Maryland	11/10/2021
Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States Oral Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/11/2021
Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study Oral Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy Oral Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction Oral Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the	12/12/2021

BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma Oral Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	
Updated Results from CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple Myeloma Oral Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium Oral Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL) Oral Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Poster	
Immune profile and optimization of dendritic cell culture from relapsed non-Hodgkin's lymphoma. International Society of Cellular Therapy Annual Meeting Miami, Florida	05/2008
Hierarchical clustering analysis of immune phenotype in non-Hodgkin's lymphoma. Pan-Pacific Lymphoma Conference Big Island, Hawaii	06/2009
Dendritic cell differentiation blockade in CD14+ monocytes in glioblastoma, non-Hodgkin lymphoma and prostate cancer patients. AACR Tumor Immunology: Basic and Clinical Advances Conference Miami Beach, Florida	12/2010
Five-year follow-up of randomized, phase II trial of idiotype-pulsed dendritic cell vaccine with adjuvant cytokines in plateau phase and post-transplant multiple myeloma. American Society of Hematology Annual Meeting Orlando, Florida	12/2010
Altered monocyte phenotype distribution predicts survival in multiple myeloma patients. Society for Immunotherapy of Cancer Annual Meeting Bethesda, Maryland	11/2012
Immune phenotype identifies different profiles of cancer patients International society of cellular therapy annual meeting Auckland, New Zealand	04/2013
Monocyte phenotype as a novel predictor of survival in untreated, newly diagnosed multiple myeloma patients. International Myeloma Working Group Meeting Kyoto, Japan	04/2013
Dendritic cell vaccine treatment for relapsed indolent B-cell non-Hodgkin lymphoma: clinical trial in progress. 12th International Conference on Malignant Lymphoma Lugano, Switzerland	06/2013
Dendritic cell vaccine treatment for relapsed indolent B-cell non-Hodgkin lymphoma:	06/2013

clinical trial in progress. 12th International Conference on Malignant Lymphoma Lugano, Switzerland	
Expression profiling of suppressive monocytes (CD14+HLA-DRlow/neg) in cancer patients. Bethesda, DC, November 2013. Poster session. Society for Immunotherapy of Cancer Annual Meeting Bethesda, District of Columbia	11/2013
Tumor monocyte cross talk promotes lymphoma cell resistance to chemotherapy. Society for Immunotherapy of Cancer Annual Meeting Washington DC, Maryland	11/2013
Immune Profiling to Predict Treatment Response from Extracorporeal Photopheresis in Graft-Versus-Host-Disease. American Society of Hematology Annual Meeting New Orleans, Louisiana	12/2013
Tumor monocyte cross talk promotes chemotherapy resistance in lymphoma. American Society of Hematology Annual Meeting New Orleans, Louisiana	12/2013
Immune Profiling to Predict Treatment Response from Extracorporeal Photopheresis in Graft-Versus-Host-Disease. February 2014, Grapevine, TX. Poster session. (*mentor to first author) Tandem BMT Meeting Dallas, Texas	02/2014
Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: clinical trial in progress. Society for Immunotherapy of Cancer Annual Meeting North Bethesda, Maryland	11/2014
Lymphoma monocyte crosstalk via Hsp27 to promote immune suppression and chemotherapy resistance. Society for Immunotherapy of Cancer Annual Meeting North Bethesda, Maryland	11/2014
Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: clinical trial in progress. American Society of Hematology Annual Meeting San Francisco, California	12/2014
Lymphoma monocyte crosstalk via Hsp27 to promote immune suppression and chemotherapy resistance. American Society of Hematology Annual Meeting San Francisco, California	12/2014
Regulatory monocytes are a novel myeloid phenotype with distinct tumor-promoting functions by both immune and non-immune mechanisms. Keystone Symposia: Tumor Immunology Banff, Alberta, Canada	02/2015
Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: clinical trial in progress. Keystone Symposia: Dendritic cells and macrophage reunited Montreal, Quebec, Canada	03/2015
Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: clinical trial in progress. International Society of Cellular Therapy Annual Meeting Las Vegas, Nevada	05/2015
Cryoablation and intra-tumor dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma. Keystone Symposia: Cancer Immunotherapy Whistler, British Columbia, Canada	03/2016

Transcriptome analysis of lymphoma edited monocyte phenotype American Society of Hematology annual meeting	12/10/2017
Peak lymphocyte count after CART infusion is a clinically accessible test that correlates with clinical response in axicabtagene ciloleucel therapy for lymphoma Mentored visiting clinical fellow on the project and presentation. American Society of Hematology annual meeting	12/09/2019
Hematologic toxicities of CAR-T cell therapy in non-Hodgkin Lymphoma Mentored pharmacist on the project and presentation. American Society of Transplant and Cell Therapy Annual Meeting Orlando, FL, Florida	02/12/2020
Infectious complications of CAR T cell therapy in non-Hodgkin lymphoma mentored APP for the project and presentation American Society of Transplant and Cell Therapy Annual Meeting Orlando, Florida	02/12/2020
Association of lymphocyte to monocyte ratio with clinical response and survival in patients with relapsed, aggressive non-Hodgkin lymphoma treatment with axicabtagene ciloleucel CAR-T mentored advanced clinical cell therapy fellow on the project and presentation American Society of Clinical Oncology Annual Meeting	06/01/2020
Cytokine release syndrome in patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel in the phase 1b/2 CARTITUDE-1 Study. American Society of Hematology annual meeting	12/07/2020
Response to bridging therapy before CAR-T cell infusion predicts outcomes for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma mentored advanced clinical cell therapy fellow on the project and presentation American society of hematology annual meeting	12/07/2020
Utility of granulocyte colony stimulating factor in patients receiving chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel mentored pharmacist on the project and presentation American Society of Hematology annual meeting	12/07/2020
Outpatient management of axicabtagene ciloleucel in aggressive lymphoma, single center experience mentored research fellow and junior faculty on the project and presentation American Society of Transplant and Cell Therapy annual meeting	02/08/2021
Response to bridging therapy before CAR-T cell infusion predicts outcomes for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma mentored project American Society of Transplant and Cell Therapy annual meeting	02/08/2021 - 02/11/2021
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis Poster Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/08/2021 - 02/12/2021
Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma Poster Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/08/2021 - 02/12/2021
Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access (EA) and Commercial out-of-Specification (OOS) Product Poster Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR	02/08/2021 - 02/12/2021

Virtual Meeting (COVID Pandemic)	
Outpatient Practice Pattern and Clinical Outcome for Axicabtagene Ciloleucel in Patients with Aggressive Lymphoma Poster Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/08/2021 - 02/12/2021
Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL) Poster Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/08/2021 - 02/12/2021
Risk of Thrombosis in CAR T-Cell Therapy in Patients Poster Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/08/2021 - 02/12/2021
Characterization of Cytokine Release Syndrome (CRS) in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma (RRMM) Poster Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/08/2021 - 12/12/2021
Long-Term Survival and Gradual Recovery of B Cells in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-cel) Poster Abstract 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Meeting (COVID Pandemic)	02/08/2021 - 12/12/2021
CARs in Myeloma: Heading Into a Traffic Jam? Poster Discussion Session 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study. Poster Abstract 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma. Poster Abstract 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T Cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. Poster Discussion Session 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma Poster Abstract 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma. Poster Abstract	06/04/2021 - 06/08/2021

2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	
Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis. Poster Abstract 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy. Poster Abstract 2021 ASCO Annual Meeting Virtual Meeting (COVID Pandemic)	06/04/2021 - 06/08/2021
An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β -NIS) Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/11/2021
Long-Term (4- and 5-Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucef (Axi-cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/11/2021
Meta-Analysis of Ciltacabtagene Autoleucef Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/11/2021
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Poster Abstract 63rd ASH Annual Meeting and Exposition	12/11/2021
A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucef CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Prognostic Role of IL-6 in POEMS Syndrome Poster Abstract	12/12/2021

63rd ASH Annual Meeting and Exposition Atlanta, Georgia	
Prophylactic Corticosteroid Use with Axicabtagene CiloleuceL (Axi-cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6) Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/12/2021
Efficacy and Safety of Ciltacabtagene AutoleuceL in Patients with Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcomes Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene CiloleuceL: Results from the US Lymphoma CAR-T Cell Consortium Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Peak Absolute Lymphocyte Count Post CAR-T Is Associated with Clinical Response and Survival Outcome in Aggressive Lymphoma Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Response to Bridging Therapy As a Predictor of Outcomes for Chimeric Antigen Receptor Therapy in Large B-Cell Lymphoma Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Vaccine Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy Poster Abstract 63rd ASH Annual Meeting and Exposition Atlanta, Georgia	12/13/2021
Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene	04/23/2022

Ciloleucel (Axi-cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL). Pre-recorded presentation 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	
Primary Analysis (PA) of Zuma-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-cel) As First-Line Therapy in Patients (Pts) with High-Risk Large B-Cell Lymphoma (LBCL) Virtual presentation 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake, Utah	04/23/2022
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 1-Year Follow-up of Zuma-1 Cohort 6 (C6) Live onsite poster presentation 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/23/2022
An Updated Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Anakinra Targeting Cytokine Release Syndrome (CRS) Associated with Chimeric Antigen Receptor T Cell (CAR-T) Therapies Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapy: Clinical Presentations, Outcomes and Management Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium Virtual Presentation 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Pre and Post-Treatment CD27+ T Cells Track with Clinical Efficacy of Axi-cel in DLBCL Patients Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Pre-Lymphodepletion & Infusion Endothelial Activation and Stress Index As a Predictor of Clinical Outcomes in CAR-T Therapy for B-Cell Lymphoma Poster Abstract	04/24/2022

2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	
Procalcitonin As a Biomarker for Prediction of Bacterial Infection in Patients Receiving Chimeric Antigen T-Cell Therapy Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Prognostic Value of Early Bone Marrow MRD Status in CAR-T Therapy for Myeloma Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Results from a Meta-Analysis of Ciltacabtagene Autoleucl compared to Physician's Choice in Patients with Relapsed or Refractory Multiple Myeloma Poster Abstract 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Salt Lake City, Utah	04/24/2022
Meta-Analysis of Ciltacabtagene Autoleucl Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Myeloma Poster Session Japanese Society of Hematology, Annual Meeting Virtual	05/22/2022
BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-Cell therapy. Poster Session 2022 ASCO Annual Meeting Chicago, Illinois	06/03/2022 - 06/07/2022
Brexucabtagene autoleucl for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States Lymphoma CAR T Consortium Poster Abstract 2022 ASCO Annual Meeting Chicago, Illinois	06/03/2022 - 06/07/2022
Ethical challenges with CAR T slot allocation with idecabtagene vicleucl manufacturing access. Poster Abstract 2022 ASCO Annual Meeting Chicago, Illinois	06/03/2022 - 06/07/2022
In-field recurrences in relapsed/refractory (R/R) B-Cell non-Hodgkin Lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART). Poster Abstract 2022 ASCO Annual Meeting Chicago, Illinois	06/03/2022 - 06/07/2022
Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity. Poster Abstract 2022 ASCO Annual Meeting Chicago, Illinois	06/03/2022 - 06/07/2022
Phase 1b/2 study of ciltacabtagene autoleucl, a BCMA-directed CAR-T Cell Therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1):	06/03/2022 - 06/07/2022

Two years post-LPI Poster Abstract 2022 ASCO Annual Meeting Chicago, Illinois	
Prognostic Value of Early Bone Marrow MRD Status in CAR-T therapy for myeloma. Poster Abstract 2022 ASCO Annual Meeting Chicago, Illinois	06/03/2022 - 06/07/2022
Treatment with anti-spike monoclonal antibodies in allogeneic HCT and CAR T-cell recipients with mild to moderate COVID-19: The Mayo Clinic Experience Poster Abstract 2022 ASCO Annual Meeting Chicago, Illinois	06/03/2022 - 06/07/2022
Ciltacabtagene Autoleucel, a BCMA-Directed CAR-T cell Therapy, in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Post LPI Results from the Phase 1b/2 CARTITUDE-1 Study Poster Presentation 2022 European Hematology Association Congress Vienna, Austria	06/10/2022

Regional**Invited**

Chimeric Antigen Receptor (CAR) T cell therapy Alliance Annual Meeting, Nursing Education Session Chicago, Illinois	05/2016
Regional Education: Future of CAR-T in Myeloma ACINDES Myeloma Course	10/12/2020
CAR-T in Myeloma Robert Kyle Symposium	05/22/2021
CAR-T Patient Selection and Management Educational presentation to Midwest regional audience OncLive State of the Science Summit: Leukemia/Lymphoma	03/17/2022

Visiting Professorship**Visiting Professorships**

First-in-human multi-center BCMA CART study in myeloma Multiple myeloma symposium, Huntsman Cancer Institute University of Utah Salt Lake City, Utah	09/28/2017 - 09/30/2017
Beijing University Invited visiting faculty Scholarly exchange to share the state of Cell Therapy at Mayo Clinic and learn about cell therapy status at Beijing University Beijing, China	06/27/2018 - 06/30/2018
CAR-T Therapy: advancing to the clinic Visit University of Winnipeg and Manitoba Cancer Care cell therapy lab, transplant and cell therapy clinical facility. Give lecture on CAR-T in practice and current research. University of Manitoba, Winnipeg, Canada	10/30/2018 - 10/31/2018
JiangSu Hospital Symposium CAR-T Therapy in the Clinic: Current State and Challenges	09/18/2021
MD Anderson Cancer Center Gave grand round talk on outpatient practice and management of patients receiving CAR-T therapy.	03/04/2022

MDACC

Clinical Practice, Interests, and Accomplishments

Lymphoma, multiple myeloma, amyloidosis, early phase immunotherapy clinical trial.

Research Interests and Accomplishments

Cancer vaccine, tumor immunology, cell therapy for immunotherapy and regenerative medicine.

Research Grants Awarded**Active Grants****Federal**

Program Director / Principal Investigator	PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma. Funded by National Cancer Institute. (R01 CA 219960)	08/2017 - 07/2023
--	---	-------------------

Program Director / Principal Investigator	Radiation and dendritic cells to hepatomas to improve immunotherapy response. Funded by National Cancer Institute. (R01 CA 274985)	09/2022 - 08/2027
--	--	-------------------

Federal sub award

Program Director / Principal Investigator	Lymphoma SPORE. Funded by National Cancer Institute. (CA 97274)	09/2017 - 06/2023
--	---	-------------------

Others	Mayo Clinic Multiple Myeloma SPORE: CAREER ENHANCEMENT PROGRAM. Funded by National Cancer Institute. (CA 186781)	09/2021 - 08/2026
--------	--	-------------------

Industry

Program Director / Principal Investigator	No Cost End Date Extension-Replacement #6: MCR CRB-401 "A Phase I Study of bb2121 in BCMA-Expressing Multiple Myeloma. Funded by Celgene. (CRB-401)	04/2015 - 04/2020
--	---	-------------------

Program Director / Principal Investigator	Replacement Am 3: KTE-C19-101 ((IRB#15-003262): A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Funded by Kite Pharmaceuticals. (KTE-C19-101)	10/2015 - 09/2017
--	---	-------------------

Program Director / Principal Investigator	Repl#4 (Add CRA EFFORT): KTE-C19-103 A Phs 1/2 Multi-Cntr Stdy Eval the Sfety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)1 ((IRB#15-003262): 5 day conditioning chemo. Funded by Kite Pharmaceuticals. (KTE-C19-103)	12/2016 - 12/2018
--	---	-------------------

Program Director / Principal Investigator	Budget Repl. #1 _Protocol Amend #2 KTE-C19-109 (IRB: 17-003421). Funded by Kite Pharmaceuticals. (KTE-C19-109)	10/2017 - 10/2019
--	--	-------------------

Program Director / Principal Investigator	Budget Replacement #1 Transform the Practice-Bio CompatiblesUK LTD MC1685 Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally after Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients with Non-Hodgkin Lymphoma . Funded by Boston Scientific Corporation	12/2017 - 11/2020
--	--	-------------------

Program Director / Principal Investigator	Budget Replacement #2 (PA#4): bb2121-MM-001 (17-009269) A Phase 2, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects with Relapsed/Refractory Multiple Myeloma. Funded by Celgene. (BB2121-MM-001)	01/2018 - 01/2022
--	---	-------------------

Program Director / Principal Investigator	Closing Enrollment: MC1782 Merck Dr Lin Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma-Merck. Funded by Merck & Co., Inc.. (54330)	04/2018 - 03/2023
Program Director / Principal Investigator	MC1782 Dr Lin Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma. Funded by Takeda Pharmaceuticals America. (X16105)	04/2018 - 04/2023
Program Director / Principal Investigator	ACT Amendment-1-CRB-402:A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma. Funded by BlueBird Bio, Inc.. (CRB-402)	04/2018 - 04/2020
Program Director / Principal Investigator	GC-LTFU-001 (17-011220) Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T Cells. Funded by Celgene. (GC-LTFU-001)	06/2018 - 06/2023
Program Director / Principal Investigator	Amendment-2-(PA #4)MCR 68284528MMY2001, A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma . Funded by Janssen Research and Development, LLC. (68284528MMY2001)	07/2019 - 07/2021
Program Director / Principal Investigator	Amdt2 to BB2121-MM-003 A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM). Funded by Celgene. (BB2121-MM-003)	09/2019 - 09/2020
Program Director / Principal Investigator	68284528MMY3002, A Phase 3 Random. Study Comparing JNJ-68284528, a CAR-T Directed Against BCMA, vs Pom., Bortezomib & Dexa. (PVd) or Daratumumab, Pom. & Dexa. (DPd) in Subjects w/ Relapsed & Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). Funded by Janssen Research and Development, LLC. (68284528MMY3002)	02/2021 - 01/2022
Program Director / Principal Investigator	BB2121-EAP-001, Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release . Funded by Celgene. (BB2121-EAP-001)	04/2021 - 04/2022
Program Director / Principal Investigator	Amdt 2 68284528MMY2003, A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2). Funded by Janssen Research and Development, LLC. (68284528MMY2003)	11/2021 - 11/2023
Program Director / Principal Investigator	68284528MMY4002, Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel . Funded by Janssen Research and Development, LLC. (68284528MMY4002 261239 L28US10021)	02/2022 - 01/2026
Program Director / Principal Investigator	68284528MMY2005, A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients with Multiple Myeloma. Funded by Janssen Research and Development, LLC. ()	06/2022 - 06/2025
Program Director / Principal Investigator	68284528MMY4007: Prospective, Multicenter, Observational Registry to Describe the Treatment of Multiple Myeloma with CAR-T and other B-Cell Maturation Antigen (BCMA)-Targeted Therapies in a Real-World Clinical Practice Setting in the United States. Funded by Janssen Research and Development, LLC. (68284528MMY4007)	08/2022 - 07/2027
Co-Investigator	Budget Replacement #2 Molecular Characteristics of Non-Hodgkin Lymphoma - Celgene Collaboration. Funded by Celgene	01/2018 - 02/2023

Mayo Clinic

Program Director / Principal Investigator	Radiation and dendritic cells to hepatomas to improve immunotherapy response (NIH Relief - Lin). Funded by NIH Relief Program	07/2022 - 06/2023
--	---	-------------------

Completed Grants**Federal**

Program Director / Principal Investigator	Lymphoma monocyte crosstalk: mechanisms of chemo-immunotherapy resistance. Funded by National Cancer Institute. (K22 CA 193674)	09/2015 - 08/2018
--	---	-------------------

Program Director / Principal Investigator	Monocyte promotion of therapy resistance by immune and non-immune mechanisms. Funded by National Cancer Institute. (R01 CA 203836)	09/2016 - 08/2021
--	--	-------------------

Federal sub award

Program Director / Principal Investigator	Neoantigen landscape in myeloma and changes with therapy. Funded by National Cancer Institute. (CA 186781)	09/2016 - 08/2017
--	--	-------------------

Program Director / Principal Investigator	Targeting Multiple Myeloma with ex vivo activated natural T-cells. Funded by National Cancer Institute. (CA 186781)	09/2018 - 08/2019
--	---	-------------------

Co-Program Director / Principal Investigator	12-010302 MCR MC1381 Phase II Study of LCL-161 Alone and in Combination with Cyclophosphamide in Patients with Relapsed Multiple Myeloma. Funded by Novartis. (Study No: CLCL161AUS01T / MC1381)	06/2013 - 06/2015
---	---	-------------------

Industry

Program Director / Principal Investigator	Replacement Am. 1 CM-2013-01: A PHASE 2 OPEN LABEL STUDY TO INVESTIGATE THE EFFICACY OF AUTOLOGOUS EBV-SPECIFIC T-CELLS FOR THE TREATMENT OF PATIENTS WITH AGGRESSIVE EXTRANODAL NK/T CELL LYMPHOMA (ENKTCL). Funded by Cell Medica. (CM-2013-01/8188600317 105)	08/2014 - 08/2016
--	--	-------------------

Program Director / Principal Investigator	Understanding immune effect of Daratumumab in myeloma patients. Funded by Janssen Research and Development, LLC	10/2015 - 09/2017
--	---	-------------------

Program Director / Principal Investigator	INTERNAL ONLY_PCS Updated_Replacement 1_Amendment 1_LTF-305: Longterm Follow-up of Subjects Treated with bb2121. Funded by BlueBird Bio, Inc.. (LTF-305)	09/2016 - 08/2021
--	--	-------------------

Program Director / Principal Investigator	CM-2015-01: A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-Specific T Cells (CMD-003) for the Treatment of Patients with EBV Positive Lymphomas. Funded by Cell Medica	10/2017 - 10/2019
--	--	-------------------

Program Director / Principal Investigator	Replacement #1 - (PA#1) KTE-C19-112: A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High Risk Large B-Cell Lymphoma. Funded by Kite Pharmaceuticals. (KTE-C19-112)	12/2018 - 12/2021
--	--	-------------------

Program Director / Principal	NDS-MM-003 A global, non-interventional, retrospective, multi-center study to generate real-world evidence of subjects with relapsed and refractory multiple myeloma with prior exposure to	05/2019 - 08/2019
------------------------------------	---	-------------------

Investigator an anti-CD38 antibody. Funded by Celgene. (NDS-MM-003)

Mayo Clinic

Program Director / Principal Investigator	Mesenchymal stromal cell therapy for patients with cardiac primary amyloidosis. Funded by Center for Regenerative Medicine	07/2013 - 12/2013
Program Director / Principal Investigator	NIH Relief Grant - Monocyte promotion of therapy resistance by immune and non-immune mechanisms. Funded by NIH Relief Program	07/2016 - 06/2017
Program Director / Principal Investigator	PD-1 blockade with cryoablation and intratumor dendritic vaccine to treat lymphoma. Funded by Richard M. Schulze Family Foundation Award in Cancer Research	07/2016 - 06/2018
Program Director / Principal Investigator	NIH Relief Grant - PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma . Funded by National Institutes of Health	09/2016 - 08/2017
Program Director / Principal Investigator	MC1685 Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally after Cryoablation and Anti-PD-1 Antibody (MK-3475) for Patients with Non-Hodgkin Lymphoma. Funded by Lupus Link Minnesota	03/2017 - 02/2022
Program Director / Principal Investigator	CAR-T Biomarker. Funded by Center for Individualized Medicine (CIM)	11/2018 - 10/2021

Inventions, Commercialization and Offering

A. Patent	Patent Number	Country	Date Filed	Date Issued
Transgenic circulating endothelial cells Yi Lin, Robert P Hebbel	6852537	US	NULL	01/2005
Treating Patients Based on Immune Subtypes Allan B. Dietz Ph.D., Michael P. Gustafson Ph.D., Yi Lin M.D., Ph.D.	10094835	USA	11/2015	10/2018

Bibliography

Peer-reviewed Articles

1. Solovey A, **Lin Y**, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. *N Engl J Med*. 1997 Nov 27; 337(22):1584-90. PMID: 9371854 DOI: 10.1056/NEJM199711273372203
2. **Lin Y**, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. *J Clin Invest*. 2000 Jan; 105(1):71-7. PMID: 10619863 PMCID: 382587 DOI: 10.1172/JCI8071
3. **Lin Y**, Chang L, Solovey A, Healey JF, Lollar P, Hebbel RP. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. *Blood*. 2002 Jan 15; 99(2):457-62. PMID: 11781225
4. Bucheit AD, Kumar S, Grote DM, **Lin Y**, von Messling V, Cattaneo RB, Fielding AK. An oncolytic measles virus engineered to enter cells through the CD20 antigen. *Mol Ther*. 2003 Jan; 7 (1):62-72 PMID: 12573619 DOI: 10.1016/s1525-0016(02)00033-3
5. Gangat N, **Lin Y**, Elkin PL. 68-year-old man with fatigue, fever, and weight loss. *Mayo Clin Proc*. 2005 Jul; 80(7):939-42. PMID: 16007900 DOI: 10.4065/80.7.939
6. Mader EK, Maeyama Y, **Lin Y**, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. *Clin Cancer Res*. 2009 Dec 1; 15 (23):7246-55 Epub 2009 Nov 24 PMID: 19934299 PMCID: 2787715 DOI: 10.1158/1078-0432.CCR-09-1292
7. Vuk-Pavlovic S, Bulur PA, **Lin Y**, Qin R, Szumlanski CL, Zhao X, Dietz AB. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. *Prostate*. 2010 Mar 1; 70 (4):443-55 PMID: 19902470 PMCID: 2935631 DOI: 10.1002/pros.21078
8. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, **Lin Y**, Dietz AB, Forsyth PA, Yong VW, Parney IF. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. *Neuro Oncol*. 2010 Apr; 12 (4):351-65 Epub 2009 Dec 22 PMID: 20308313 PMCID: 2940603 DOI: 10.1093/neuonc/nop023
9. Gustafson MP, **Lin Y**, New KC, Bulur PA, O'Neill BP, Gastineau DA, Dietz AB. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. *Neuro Oncol*. 2010 Jul; 12 (7):631-44 Epub 2010 Feb 23 PMID: 20179016 PMCID: 2940665 DOI: 10.1093/neuonc/noq001
10. **Lin Y**, Hogan WJ. Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease. *Adv Hematol*. 2011; 2011:427863 Epub 2011 Dec 10 PMID: 22190941 PMCID: 3235491 DOI: 10.1155/2011/427863
11. **Lin Y**, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. *Blood*. 2011 Jan 20; 117 (3):872-81 Epub 2010 Nov 09 PMID: 21063024 PMCID: 3035079 DOI: 10.1182/blood-2010-05-283820
12. Gustafson MP, **Lin Y**, LaPlant B, Liwski CJ, Maas ML, League SC, Bauer PR, Abraham RS, Tollefson MK, Kwon ED, Gastineau DA, Dietz AB. Immune monitoring using the predictive power of immune profiles. *J Immunother Cancer*. 2013; 1:7. Epub 2013 Jun 27. PMID: 25512872 PMCID: 4266565 DOI: 10.1186/2051-1426-1-7
13. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, **Lin Y**, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. *Mayo Clin Proc*. 2013 Apr; 88 (4):360-76 PMID: 23541011 DOI: 10.1016/j.mayocp.2013.01.019
14. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, **Lin Y**, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. *Am J Hematol*. 2013 May; 88(5):375-8. Epub 2013 Mar 19. PMID: 23508840 DOI: 10.1002/ajh.23413
15. Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, **Lin Y**, Leung N, Dispenzieri A. Outcomes of patients with POEMS syndrome treated initially with radiation. *Blood*. 2013 Jul 4; 122 (1):68-73 Epub 2013 May 22 PMID: 23699599 PMCID: 4067496 DOI: 10.1182/blood-2013-03-487025
16. Gonsalves WI, Gertz MA, Dispenzieri A, Lacy MQ, **Lin Y**, Singh PP, Gupta V, Hayman SR, Buadi FK, Dingli D, Kapoor P, McCurdy AR, Kumar SK. Implications of continued response after autologous stem cell transplantation for multiple myeloma. *Blood*. 2013 Sep 5; 122 (10):1746-9 Epub 2013 July 17 PMID: 23863899 PMCID: 3765057 DOI: 10.1182/blood-2013-03-492678
17. * Hegerova LT, **Lin Y**. Disseminated histoplasmosis: a cause of hemophagocytic syndrome. *Mayo Clin Proc*. 2013 Oct; 88(10):e123. PMID: 24079697 DOI: 10.1016/j.mayocp.2013.04.030

18. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, **Lin Y**, Kapoor P, Rajkumar SV, McCurdy A, Dispenzieri A. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *J Clin Oncol*. 2013 Dec 1; 31 (34):4319-24 Epub 2013 Oct 21 PMID: 24145344 PMCID: 4881366 DOI: 10.1200/JCO.2013.50.8499
19. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, **Lin Y**, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? *Blood*. 2013 Dec 19; 122 (26):4172-81 Epub 2013 Oct 21 PMID: 24144641 PMCID: 3952477 DOI: 10.1182/blood-2013-08-520890
20. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, **Lin Y**, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. *J Clin Oncol*. 2013 Dec 20; 31 (36):4529-35 Epub 2013 Nov 18 PMID: 24248686 PMCID: 3871514 DOI: 10.1200/JCO.2013.49.0086
21. Laborde RR, **Lin Y**, Gustafson MP, Bulur PA, Dietz AB. Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)-HLA-DR(lo/neg) Cells): The Gateway to Improved Responses. *Front Immunol*. 2014; 5:147 Epub 2014 Apr 04 PMID: 24772111 PMCID: 3983500 DOI: 10.3389/fimmu.2014.00147
22. Gustafson MP, **Lin Y**, Ryder M, Dietz AB. Strategies for improving the reporting of human immunophenotypes by flow cytometry. *J Immunother Cancer*. 2014; 2:18 Epub 2014 June 18 PMID: 24982762 PMCID: 4075421 DOI: 10.1186/2051-1426-2-18
23. Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, **Lin Y**, Kapoor P, Go R, Rajkumar SV, Dispenzieri A. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. *Am J Hematol*. 2014 Mar; 89 (3):302-5 Epub 2014 Feb 18 PMID: 24265187 DOI: 10.1002/ajh.23634
24. Kourelis TV, Kumar SK, Go RS, Kapoor P, Kyle RA, Buadi FK, Gertz MA, Lacy MQ, Hayman SR, Leung N, Dingli D, Lust JA, **Lin Y**, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. *Am J Hematol*. 2014 Nov; 89(11):1051-4. Epub 2014 Sep 02. PMID: 25111004 DOI: 10.1002/ajh.23827
25. Witzig TE, Maurer MJ, Habermann TM, Link BK, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Markovic SN, Johnston PB, **Lin Y**, Thompson C, Gupta M, Katzmann JA, Cerhan JR. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma. *Am J Hematol*. 2014 Dec; 89 (12):1116-20 Epub 2014 Sept 26 PMID: 25228125 PMCID: 4362722 DOI: 10.1002/ajh.23839
26. Gustafson MP, **Lin Y**, Maas ML, Van Keulen VP, Johnston PB, Peikert T, Gastineau DA, Dietz AB. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. *PLoS One*. 2015; 10(3):e0121546. Epub 2015 Mar 23. PMID: 25799053 PMCID: 4370675 DOI: 10.1371/journal.pone.0121546
27. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, **Lin Y**, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. *Am J Hematol*. 2015 Mar; 90 (3):181-6 Epub 2015 Jan 16 PMID: 25388651 PMCID: 5780648 DOI: 10.1002/ajh.23898
28. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, **Lin Y**, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, Kumar SK. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. *Blood Cancer J*. 2015 Mar 20; 5:e296 PMID: 25794132 PMCID: 4382661 DOI: 10.1038/bcj.2015.20
29. * Zhang ZJ, Bulur PA, Dogan A, Gastineau DA, Dietz AB, Lin Y, **Lin Y**. Immune independent crosstalk between lymphoma and myeloid suppressor CD14(+)-HLA-DR(low/neg) monocytes mediates chemotherapy resistance. *Oncimmunology*. 2015 Apr; 4 (4):e996470 Epub 2015 Jan 26 PMID: 26137410 PMCID: 4485750 DOI: 10.1080/2162402X.2014.996470
30. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Ketterling RP, **Lin Y**, Russell S, Hwa L, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Dispenzieri A. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. *Blood Cancer J*. 2015 May 1; 5:e310 Epub 2015 May 01 PMID: 25933374 PMCID: 4423220 DOI: 10.1038/bcj.2015.34
31. Xiu B, **Lin Y**, Grote DM, Ziesmer SC, Gustafson MP, Maas ML, Zhang Z, Dietz AB, Porrata LF, Novak AJ, Liang AB, Yang ZZ, Ansell SM. IL-10 induces the development of immunosuppressive CD14(+)-HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma. *Blood Cancer J*. 2015 Jul 31; 5:e328 Epub 2015 July 31 PMID: 26230952 PMCID: 4526782 DOI: 10.1038/bcj.2015.56
32. Gustafson MP, **Lin Y**, Bleeker JS, Warad D, Tollefson MK, Crispen PL, Bulur PA, Harrington SM, Laborde RR,

Gastineau DA, Leibovich BC, Cheville JC, Kwon ED, Dietz AB. Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. *Clin Cancer Res*. 2015 Sep 15; 21 (18):4224-33 Epub 2015 May 21 PMID: 25999436 DOI: 10.1158/1078-0432.CCR-15-0260

33. Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, **Lin Y**, Go RS, Hwa YL, Kyle RA, Kumar SK. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. *Am J Hematol*. 2015 Oct; 90: (10)888-91. PMID: 26148022 DOI: 10.1002/ajh.24107
34. Cordes S, Gertz MA, Buadi FK, **Lin Y**, Lacy MQ, Kapoor P, Kumar SK, McCurdy A, Dispenzieri A, Dingli D, Hayman SR, Hogan WJ, Pruthi RK. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. *Blood Coagul Fibrinolysis*. 2016 Jan; 27: (1)101-8. PMID: 26218969 DOI: 10.1097/MBC.0000000000000367
35. Olson MC, Atwell TD, Harmsen WS, Konrad A, King RL, **Lin Y**, Wall DJ. Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen. *AJR Am J Roentgenol*. 2016 Mar; 206 (3):655-9 PMID: 26901024 DOI: 10.2214/AJR.15.15125
36. Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, **Lin Y**, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK. Clinical characteristics and outcomes in biclonal gammopathies. *Am J Hematol*. 2016 May; 91 (5):473-5 Epub 2016 Apr 06 PMID: 26840395 PMID: 5780647 DOI: 10.1002/ajh.24319
37. Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, **Lin Y**, Leung N, Hwa YL, Gonsalves W, Kyle RA, Dispenzieri A. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. *Leukemia*. 2016 May; 30 (5):1079-85 Epub 2015 Dec 16 PMID: 26669974 DOI: 10.1038/leu.2015.344
38. Kourelis TV, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Dingli D, Go RS, Kapoor P, Lust JA, Hayman SR, Hwa Y, Rajkumar SV, Zeldenrust SR, Russell SJ, **Lin Y**, Leung N, Kyle RA, Gonsalves WI, Dispenzieri A. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. *Am J Hematol*. 2016 Jun; 91 (6):585-9 Epub 2016 Apr 13 PMID: 26972803 DOI: 10.1002/ajh.24356
39. Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, **Lin Y**, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. *Blood Cancer J*. 2016 Jul 29; 6 (7):e454 Epub 2016 July 29 PMID: 27471870 PMID: 5030386 DOI: 10.1038/bcj.2016.65
40. Higgins LS, Go RS, Dingli D, Kumar SK, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lust JA, Kapoor P, Leung N, **Lin Y**, Kourelis TV, Gertz MA, Kyle RA, Gonsalves WI. Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. *Clin Lymphoma Myeloma Leuk*. 2016 Aug; 16 (8):447-52 Epub 2016 May 05 PMID: 27238425 DOI: 10.1016/j.clml.2016.04.009
41. Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, **Lin Y**, Gonsalves WI, Go RS, Gertz MA. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. *Nephrol Dial Transplant*. 2016 Aug; 31 (8):1284-9 Epub 2015 Nov 30 PMID: 26627634 DOI: 10.1093/ndt/gfv328
42. Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. *Haematologica*. 2016 Sep; 101 (9):1102-9 Epub 2016 June 16 PMID: 27479823 PMID: 5060027 DOI: 10.3324/haematol.2016.147041
43. * Marin-Argany M, **Lin Y**, Misra P, Williams A, Wall JS, Howell KG, Elsbernd LR, McClure M, Ramirez-Alvarado M. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING. *J Biol Chem*. 2016 Sep 16; 291 (38):19813-25 Epub 2016 July 26 PMID: 27462073 PMID: 5025671 DOI: 10.1074/jbc.M116.736736
44. Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, Rajkumar SV, Go RS, Leung N, Kapoor P, Dingli D, Kyle RA, Russell S, Lust JA, Hayman SR, **Lin Y**, Zeldenrust S, Dispenzieri A. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. *Am J Hematol*. 2016 Oct; 91 (10):984-8 Epub 2016 July 14 PMID: 27341539 DOI: 10.1002/ajh.24453
45. Muchtar E, Derudas D, Mauermann M, Liewluck T, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. *Mayo Clin Proc*. 2016 Oct; 91: (10)1354-1361. PMID: 27712634 DOI: 10.1016/j.mayocp.2016.06.027
46. Paludo J, Painuly U, Kumar S, Gonsalves WI, Rajkumar V, Buadi F, Lacy MQ, Dispenzieri A, Kyle RA,

- Mauermann ML, McCurdy A, Dingli D, Go RS, Hayman SR, Leung N, Lust JA, **Lin Y**, Gertz MA, Kapoor P. Myelomatous Involvement of the Central Nervous System. *Clin Lymphoma Myeloma Leuk*. 2016 Nov; 16 (11):644-654 Epub 2016 Aug 10 PMID: 27624224 DOI: 10.1016/j.clml.2016.08.010
47. Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, **Lin Y**, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2016 Nov; 91 (11):1129-1134 Epub 2016 Aug 29 PMID: 27508522 PMCID: 5129512 DOI: 10.1002/ajh.24532
 48. Kourelis TV, Nasr SH, Dispenzieri A, Kumar SK, Gertz MA, Fervenza FC, Buadi FK, Lacy MQ, Erickson SB, Cosio FG, Kapoor P, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, **Lin Y**, Gonsalves W, Lorenz EC, Zand L, Kyle RA, Leung N. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. *Am J Hematol*. 2016 Nov; 91 (11):1123-1128 Epub 2016 Aug 29 PMID: 27501122 DOI: 10.1002/ajh.24528
 49. Abcejo AS, Sviggum HP, Mauermann ML, Hebl JR, Mantilla CB, Hanson AC, **Lin Y**, Jacob AK. Perioperative Nerve Injury After Peripheral Nerve Block in Patients With Previous Systemic Chemotherapy. *Reg Anesth Pain Med*. 2016 Nov/Dec; 41 (6):685-690 PMID: 27753708 DOI: 10.1097/AAP.0000000000000492
 50. Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, **Lin Y**, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. *Blood*. 2016 Nov 17; 128 (20):2415-2422 Epub 2016 Oct 04 PMID: 27702799 PMCID: 5114487 DOI: 10.1182/blood-2016-05-717769
 51. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, **Lin Y**, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. *Nat Med*. 2016 Dec; 22 (12):1411-1420 Epub 2016 Nov 14 PMID: 27841872 PMCID: 5515246 DOI: 10.1038/nm.4229
 52. Hwa YL, Shi Q, Kumar SK, Lacy MQ, Gertz MA, Kapoor P, Buadi FK, Leung N, Dingli D, Go RS, Hayman SR, Gonsalves WI, Russell S, Lust JA, **Lin Y**, Rajkumar SV, Dispenzieri A. Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. *Am J Hematol*. 2017 Jan; 92 (1):50-55 Epub 2016 Nov 18 PMID: 27733010 PMCID: 5217079 DOI: 10.1002/ajh.24582
 53. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, **Lin Y**, Kapoor P, Go R, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Leukemia*. 2017 Jan; 31 (1):92-99 Epub 2016 May 23 PMID: 27211265 DOI: 10.1038/leu.2016.140
 54. * Javeed N, Gustafson MP, Dutta SK, **Lin Y**, Bamlet WR, Oberg AL, Petersen GM, Chari ST, Dietz AB, Mukhopadhyay D. Immunosuppressive CD14(+)HLA-DR(lo/neg) monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes. *Oncimmunology*. 2017; 6 (1):e1252013 Epub 2016 Nov 02 PMID: 28197368 PMCID: 5283619 DOI: 10.1080/2162402X.2016.1252013
 55. Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, **Lin Y**, Go RS, Chakraborty R, Zeldenrust S, Kumar SK, Kyle RA, Rajkumar SV, Gertz MA. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. *Blood*. 2017 Jan 5; 129 (1):82-87 Epub 2016 Oct 11 PMID: 27729322 DOI: 10.1182/blood-2016-06-721878
 56. Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR, Leung N, Go RS, Dingli D, Kapoor P, **Lin Y**, Hwa YL, Fonder AL, Hobbs MA, Zeldenrust SR, Lust JA, Gonsalves WI, Russell SJ, Kumar SK. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. *Blood Cancer J*. 2017 Feb 17; 7 (2):e528 PMID: 28211889 PMCID: 5386331 DOI: 10.1038/bcj.2017.13
 57. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, **Lin Y**, Kapoor P, Go R, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Amyloid* 2017 Mar; 24 (sup1):40-41 PMID: 28434371 DOI: 10.1080/13506129.2016.1277696
 58. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Chakraborty R, Russell S, Dingli D, Lust JA, **Lin Y**, Kapoor P, Go R, Kyle RA, Rajkumar VS, Gertz MA. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. *Amyloid* 2017 Mar; 24 (sup1):44-45 PMID: 28434304 DOI: 10.1080/13506129.2017.1281117
 59. Riester SM, Denbeigh JM, **Lin Y**, Jones DL, de Mooij T, Lewallen EA, Nie H, Paradise CR, Radel DJ, Dudakovic A, Camilleri ET, Larson DR, Qu W, Krych AJ, Frick MA, Im HJ, Dietz AB, Smith J, van Wijnen AJ.

Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial. *Stem Cells Transl Med.* 2017 Mar; 6(3):910-922. Epub 2016 Oct 26. PMID: 28297568 PMCID: 5442773 DOI: 10.5966/sctm.2016-0097

60. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, **Lin Y**, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clin Proc.* 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11 PMID: 28291589 PMCID: 5554888 DOI: 10.1016/j.mayocp.2017.01.003
61. Mughtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Dispenzieri A. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. *Blood.* 2017 Apr 13; 129 (15):2111-2119 Epub 2017 Jan 26 PMID: 28126928 PMCID: 5391625 DOI: 10.1182/blood-2016-11-751628
62. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, **Lin Y**, Russell S, Kapoor P, Go RS, Kourelis T, Gonsalves W, Zeldenrust SR, Kyle RA, Vincent Rajkumar S, Zemla T, Sloan J, Dispenzieri A. Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. *Am J Hematol.* 2017 May; 92: (5)435-440. PMID: 28181278 DOI: 10.1002/ajh.24676
63. Kourelis TV, Kyle RA, Dingli D, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Kapoor P, Go RS, Gonsalves WI, Warsame R, Lust JA, Hayman SR, Rajkumar SV, Zeldenrust SR, Russell SJ, **Lin Y**, Leung N, Dispenzieri A. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. *Mayo Clin Proc.* 2017 Jun; 92 (6):908-917 Epub 2017 May 05 PMID: 28483059 DOI: 10.1016/j.mayocp.2017.02.016
64. Mughtar E, Dean DS, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, **Lin Y**, Warsame R, Gonsalves W, Kourelis TV, Go RS, Chakraborty R, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. *J Intern Med.* 2017 Jun; 281 (6):611-619 Epub 2017 Apr 24 PMID: 28439924 DOI: 10.1111/joim.12617
65. Ravi P, Kumar S, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, **Lin Y**, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. *Blood Cancer J.* 2017 Jun 16; 7 (6):e569 Epub 2017 June 16 PMID: 28622306 PMCID: 5584483 DOI: 10.1038/bcj.2017.46
66. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, **Lin Y**, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. *Blood.* 2017 Jun 29; 129 (26):3419-3427 Epub 2017 Apr 19 PMID: 28424162 PMCID: 5492091 DOI: 10.1182/blood-2017-02-765685
67. Mughtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. *Leukemia.* 2017 Jul; 31 (7):1562-1569 Epub 2016 Dec 01 PMID: 27904139 DOI: 10.1038/leu.2016.369
68. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, **Lin Y**, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncol.* 2017 Sep 1; 3 (9):1257-1265 PMID: 28056114 PMCID: 5556979 DOI: 10.1001/jamaoncol.2016.5763
69. Mughtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Dingli D, Leung N, Rajkumar SV, Kyle RA, Kumar SK, Gertz MA. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. *Br J Haematol.* 2017 Sep; 178 (6):888-895 Epub 2017 July 12 PMID: 28699650 PMCID: 5591068 DOI: 10.1111/bjh.14830
70. Ghosh T, Gonsalves WI, Jevremovic D, Dispenzieri A, Dingli D, Timm MM, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, **Lin Y**, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Kyle RA, Gertz MA, Vincent Rajkumar S, Kumar SK. The prognostic significance of polyclonal bone

- marrow plasma cells in patients with relapsing multiple myeloma. *Am J Hematol*. 2017 Sep; 92(9):E507-E512. Epub 2017 Jul 19. PMID: 28568244 PMCID: 5546938 DOI: 10.1002/ajh.24807
71. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, **Lin Y**, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. *Blood*. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06 PMID: 28684537 PMCID: 5606008 DOI: 10.1182/blood-2017-05-782961
 72. Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, Macon W, Syrbu S, Lin T, **Lin Y**, Ansell SM, Nowakowski GS, Habermann TM, Cerhan JR, Link BK. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. *Br J Haematol*. 2017 Oct; 179 (1):50-60 Epub 2017 June 27 PMID: 28653407 PMCID: 5612860 DOI: 10.1111/bjh.14813
 73. Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, **Lin Y**, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia. *Br J Haematol*. 2017 Oct; 179 (1):98-105 Epub 2017 Aug 08 PMID: 28786474 DOI: 10.1111/bjh.14826
 74. Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK, Gonsalves WI, Leung N, Dispenzieri A, Kourelis TV, Go RS, Lacy MQ, Hobbs MA, **Lin Y**, Warsame R, Lust J, Fonder AL, Hwa YL, Hayman SR, Russell SJ, Kyle RA, Gertz MA, Kapoor P. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. *Am J Hematol*. 2017 Nov; 92 (11):1146-1155 Epub 2017 Sept 08 PMID: 28799231 DOI: 10.1002/ajh.24883
 75. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Rajkumar SV, Dingli D, Leung N, Kyle RA, Kumar SK, Gertz MA. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. *Ann Med*. 2017 Nov; 49 (7):545-551 Epub 2017 Mar 27 PMID: 28271734 DOI: 10.1080/07853890.2017.1304649
 76. **Lin Y**, Marin-Argany M, Dick CJ, Redhage KR, Blancas-Mejia LM, Bulur P, Butler GW, Deeds MC, Madden BJ, Williams A, Wall JS, Dietz A, Ramirez-Alvarado M. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. *Cytotherapy*. 2017 Dec; 19 (12):1426-1437 Epub 2017 Oct 14 PMID: 29037943 PMCID: 6456258 DOI: 10.1016/j.jcyt.2017.08.021
 77. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, **Lin Y**, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wieszorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*. 2017 Dec 28; 377 (26):2531-2544 Epub 2017 Dec 10 PMID: 29226797 PMCID: 5882485 DOI: 10.1056/NEJMoa1707447
 78. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, **Lin Y**, Jain N, Daver N, Westin J, Gulbis AM, Lohin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nat Rev Clin Oncol*. 2018 Jan; 15 (1):47-62 Epub 2017 Sept 19 PMID: 28925994 PMCID: 6733403 DOI: 10.1038/nrclinonc.2017.148
 79. Lakshman A, Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, **Lin Y**, Kourelis TV, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Natural history of t(11;14) multiple myeloma. *Leukemia*. 2018 Jan; 32 (1):131-138 Epub 2017 June 27 PMID: 28655925 DOI: 10.1038/leu.2017.204
 80. Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, **Lin Y**, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *Am J Hematol*. 2018 Feb; 93 (2):179-186 Epub 2017 Nov 10 PMID: 29067723 DOI: 10.1002/ajh.24954
 81. Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, **Lin Y**, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. *Am J Hematol*. 2018 Feb; 93 (2):187-194 Epub 2017 Nov 17 PMID: 29080258 DOI: 10.1002/ajh.24955
 82. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA,

- Gonsalves WI, Reeder CB, **Lin Y**, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. *Leukemia*. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01 PMID: 28860655 DOI: 10.1038/leu.2017.258
83. Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, **Lin Y**, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circ Cardiovasc Imaging*. 2018 May; 11 (5):e006588 PMID: 29752392 PMCID: 5963522 DOI: 10.1161/CIRCIMAGING.117.006588
 84. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, **Lin Y**, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, Kumar SK, Gonsalves WI. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. *Leukemia*. 2018 Jun; 32 (6):1421-1426 Epub 2018 Feb 21 PMID: 29483709 PMCID: 5992020 DOI: 10.1038/s41375-018-0063-7
 85. Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, **Lin Y**, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer J*. 2018 Jun 12; 8 (6):59 Epub 2018 June 12 PMID: 29895887 PMCID: 5997745 DOI: 10.1038/s41408-018-0077-4
 86. Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, **Lin Y**, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. *Blood Cancer J*. 2018 Jul 30; 8 (8):70 Epub 2018 July 30 PMID: 30061664 PMCID: 6066484 DOI: 10.1038/s41408-018-0106-3
 87. Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, **Lin Y**, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. *Ann Hematol*. 2018 Aug; 97 (8):1417-1425 Epub 2018 Apr 03 PMID: 29610969 DOI: 10.1007/s00277-018-3311-z
 88. Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, **Lin Y**, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*. 2018 Aug; 32 (8):1811-1815 Epub 2018 Jan 30 PMID: 29568092 DOI: 10.1038/s41375-018-0030-3
 89. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, **ATTR-ACT Study Investigators**. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *N Engl J Med*. 2018 Sep 13; 379 (11):1007-1016 Epub 2018 Aug 27 PMID: 30145929 DOI: 10.1056/NEJMoa1805689
 90. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. *Leukemia*. 2018 Oct; 32 (10):2240-2249 Epub 2018 Feb 20 PMID: 29581546 DOI: 10.1038/s41375-018-0060-x
 91. Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Zeldenrust S, Lust J, Russell S, Leung N, Kapoor P, Go R, **Lin Y**, Gonsalves W, Kourelis T, Warsame R, Kyle R, Kumar S. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. *Am J Hematol*. 2018 Oct; 93 (10):1207-1210 Epub 2018 Aug 15 PMID: 30016549 DOI: 10.1002/ajh.25215
 92. Cohen DA, Lopez-Chiriboga AS, Pittock SJ, Gadoth A, Zekeridou A, Boilson BA, Hogan WJ, Poterucha JJ, Wilton KM, **Lin Y**, Flanagan EP. Posttransplant autoimmune encephalitis. *Neurol Neuroimmunol Neuroinflamm*. 2018 Nov; 5(6):e497. Epub 2018 Aug 20. PMID: 30175169 PMCID: 6117190 DOI: 10.1212/NXI.0000000000000497
 93. Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, **Lin Y**, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia. *Am J Hematol*. 2018 Nov; 93 (11):1384-1393 Epub 2018 Oct 02 PMID: 30121949 DOI: 10.1002/ajh.25254

94. Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, **Lin Y**, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. *Blood Cancer J.* 2018 Nov 15; 8 (12):116 PMID: 30442928 PMCID: 6238010 DOI: 10.1038/s41408-018-0140-1
95. Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, **Lin Y**, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. *Blood Cancer J.* 2018 Dec 11; 8 (12):125 PMID: 30538223 PMCID: 6289963 DOI: 10.1038/s41408-018-0163-7
96. Mughtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. *Amyloid.* 2019; 26(sup1):101-102. PMID: 31343331 DOI: 10.1080/13506129.2019.1582486
97. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, **Lin Y**, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol.* 2019 Jan; 20 (1):31-42 Epub 2018 Dec 02 PMID: 30518502 PMCID: 6733402 DOI: 10.1016/S1470-2045(18)30864-7
98. Mughtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, **Lin Y**, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. *Leukemia.* 2019 Feb; 33 (2):527-531 Epub 2018 Sept 26 PMID: 30258095 DOI: 10.1038/s41375-018-0258-y
99. Mughtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. *Mayo Clin Proc.* 2019 Mar; 94 (3):472-483 Epub 2019 Feb 13 PMID: 30770096 DOI: 10.1016/j.mayocp.2018.08.006
100. Mughtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Comparative analysis of staging systems in AL amyloidosis. *Leukemia* 2019 Mar; 33 (3):811-814 Epub 2019 Jan 23 PMID: 30675009 DOI: 10.1038/s41375-018-0370-z
101. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Mughtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, **Lin Y**, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone Marrow Transplant.* 2019 Mar; 54 (3):353-367 Epub 2018 July 09 PMID: 29988062 PMCID: 6463224 DOI: 10.1038/s41409-018-0264-8
102. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, **Lin Y**, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Natural history of multiple myeloma with de novo del(17p). *Blood Cancer J.* 2019 Mar 7; 9 (3):32 Epub 2019 Mar 07 PMID: 30846679 PMCID: 6405846 DOI: 10.1038/s41408-019-0191-y
103. * Raje N, Berdeja J, **Lin Y**#, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. *N Engl J Med.* 2019 May 2; 380 (18):1726-1737 PMID: 31042825 PMCID: 8202968 DOI: 10.1056/NEJMoa1817226
104. Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, **Lin Y**, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. *Am J Hematol.* 2019 Jul; 94 (7):751-756 Epub 2019 Apr 30 PMID: 30945330 DOI: 10.1002/ajh.25481
105. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, **Lin Y**,

- Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Impact of acquired del(17p) in multiple myeloma. *Blood Adv*. 2019 Jul 9; 3 (13):1930-1938 PMID: 31248884 PMCID: 6616261 DOI: 10.1182/bloodadvances.2018028530
106. Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, **Lin Y**, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. *Br J Haematol*. 2019 Dec; 187 (5):588-594 Epub 2019 July 12 PMID: 31298751 PMCID: 6872910 DOI: 10.1111/bjh.16096
 107. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, **Lin Y**. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2019 Dec; 25 (12):2305-2321 Epub 2019 Aug 22 PMID: 31446199 DOI: 10.1016/j.bbmt.2019.08.015
 108. Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, **Lin Y**, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. *Clin Lymphoma Myeloma Leuk*. 2020 Jan; 20 (1):53-56 Epub 2019 Oct 09 PMID: 31685378 PMCID: 6960347 DOI: 10.1016/j.clml.2019.09.624
 109. Ren Y, Cherukuri Y, Wickland DP, Sarangi V, Tian S, Carter JM, Mansfield AS, Block MS, Sherman ME, Knutson KL, **Lin Y**, Asmann YW. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. *Oncoimmunology*. 2020; 9 (1):1744947 Epub 2020 Apr 01 PMID: 32523802 PMCID: 7255108 DOI: 10.1080/2162402X.2020.1744947
 110. Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, **Lin Y**, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. *Blood Cancer J*. 2020 Jan 8; 10 (1):4 Epub 2020 Jan 08 PMID: 31913261 PMCID: 6949262 DOI: 10.1038/s41408-019-0266-9
 111. Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, **Lin Y**, Go RS, Siddiqui MA, Kyle RA, Gertz MA, Rajkumar SV, Kumar SK. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. *Am J Hematol*. 2020 Mar; 95 (3):310-315 Epub 2020 Jan 08 PMID: 31867775 PMCID: 7724649 DOI: 10.1002/ajh.25709
 112. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, **Lin Y**, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. *Am J Hematol*. 2020 Mar; 95(3):274-281. Epub 2019 Dec 31. PMID: 31814157 DOI: 10.1002/ajh.25697
 113. Tschautscher M, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Russell S, Leung N, Go R, **Lin Y**, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Rajkumar V, Kumar S. Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. *Am J Hematol* 2020 Mar; 95 (3):E60-E62 Epub 2019 Dec 30 PMID: 31840857 DOI: 10.1002/ajh.25702
 114. Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, **Lin Y**, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. *Amyloid*. 2020 Mar; 27 (1):13-16 Epub 2019 Sept 23 PMID: 31544536 PMCID: 7372715 DOI: 10.1080/13506129.2019.1666709
 115. Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, Warsame R, Russell S, Lust JA, **Lin Y**, Zeldenrust S, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. *Leukemia*. 2020 Apr; 34 (4):1135-1143 Epub 2019 Nov 22 PMID: 31758090 DOI: 10.1038/s41375-019-0655-x
 116. Ansell SM, **Lin Y**. Immunotherapy of lymphomas. *J Clin Invest*. 2020 Apr 1; 130 (4):1576-1585 PMID: 32039913 PMCID: 7108914 DOI: 10.1172/JCI129206

117. Xia Z, Su YR, Petersen P, Qi L, Kim AE, Figueiredo JC, **Lin Y**, Nan H, Sakoda LC, Albanes D, Berndt SI, Bezieau S, Bien S, Buchanan DD, Casey G, Chan AT, Conti DV, Drew DA, Gallinger SJ, Gauderman WJ, Giles GG, Gruber SB, Gunter MJ, Hoffmeister M, Jenkins MA, Joshi AD, Le Marchand L, Lewinger JP, Li L, Lindor NM, Moreno V, Murphy N, Nassir R, Newcomb PA, Ogino S, Rennert G, Song M, Wang X, Wolk A, Woods MO, Brenner H, White E, Slattery ML, Giovannucci EL, Chang-Claude J, Pharoah PDP, Hsu L, Campbell PT, Peters U. Functional informed genome-wide interaction analysis of body mass index, diabetes and colorectal cancer risk. *Cancer Med.* 2020 May; 9 (10):3563-3573 Epub 2020 Mar 24 PMID: 32207560 PMCID: 7221445 DOI: 10.1002/cam4.2971
118. * Jordan TL, Maar K, Redhage KR, Misra P, Blancas-Mejia LM, Dick CJ, Wall JS, Williams A, Dietz AB, van Wijnen AJ, **Lin Y**, Ramirez-Alvarado M. Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. *Leukemia.* 2020 May; 34 (5):1383-1393 Epub 2019 Dec 03 PMID: 31796914 PMCID: 7196017 DOI: 10.1038/s41375-019-0640-4
119. Evans LA, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Go R, Russell S, Lust JA, **Lin Y**, Siddiqui M, Kyle RA, Gertz MA, Rajkumar SV, Kumar SK, Gonsalves WI. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. *Am J Hematol.* 2020 Jun; 95 (6):637-642 Epub 2020 Mar 26 PMID: 32129510 PMCID: 7217733 DOI: 10.1002/ajh.25773
120. Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, **Lin Y**, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. *J Immunother Cancer.* 2020 Jul; 8 (2) PMID: 32661116 PMCID: 7359060 DOI: 10.1136/jitc-2020-000734
121. Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, **Lin Y**, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, Athale J, Shah NN, Kochenderfer JN, Dharshan A, Beitinjaneh A, Arias AS, McEvoy C, Mead E, Stephens RS, Nates JL, Neelapu SS, Pastores SM. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. *J Crit Care* 2020 Aug; 58:58-64 Epub 2020 Apr 15 PMID: 32361219 PMCID: 7321897 DOI: 10.1016/j.jcrc.2020.04.008
122. Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, **Lin Y**, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, Athale J, Shah NN, Kochenderfer JN, Dharshan A, Beitinjaneh A, Arias AS, McEvoy C, Mead E, Stephens RS, Nates JL, Neelapu SS, Pastores SM. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. *J Crit Care.* 2020 Aug; 58:58-64. Epub 2020 Apr 15. PMID: 32361219 PMCID: 7321897 DOI: 10.1016/j.jcrc.2020.04.008
123. Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, **Lin Y**, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Rajkumar SV, Kumar SK. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Adv.* 2020 Aug 11; 4 (15):3509-3519 PMID: 32750129 PMCID: 7422105 DOI: 10.1182/bloodadvances.2020002218
124. Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, **Lin Y**, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer J.* 2020 Aug 11; 10 (8):82 PMID: 32782240 PMCID: 7419564 DOI: 10.1038/s41408-020-00348-5
125. Paquin A, Visram A, Kumar SK, Gertz MA, Cantwell H, Buadi FK, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, **Lin Y**, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. *Blood Cancer J.* 2020 Aug 28; 10 (8):87 PMID: 32859899 PMCID: 7455690 DOI: 10.1038/s41408-020-00353-8
126. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, **Lin Y**, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bannani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. *J Clin Oncol.* 2020 Sep 20; 38 (27):3119-3128 Epub 2020 May 13 PMID: 32401634 PMCID: 7499611 DOI: 10.1200/JCO.19.02104
127. Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Russell S, Lust JA, **Lin Y**, Zeldenrust S, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A. Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. *Leukemia.* 2020 Oct; 34 (10):2819 PMID: 32728185 DOI: 10.1038/s41375-020-0993-8
128. Tschautscher MA, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L,

- Fonder A, Hobbs M, Hayman S, Lust J, Russell SJ, Leung N, Go RS, **Lin Y**, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Vincent Rajkumar S, Kumar S. Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. *Blood Cancer J* 2020 Oct 2; 10 (10):95 Epub 2020 Oct 02 PMID: 33009363 PMCID: 7532166 DOI: 10.1038/s41408-020-00363-6
129. Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, **Lin Y**, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. *Blood Adv.* 2020 Oct 13; 4 (19):4898-4911 PMID: 33035333 PMCID: 7556133 DOI: 10.1182/bloodadvances.2020002394
 130. Block MS, Dietz AB, Gustafson MP, Kalli KR, Erskine CL, Youssef B, Vijay GV, Allred JB, Pavelko KD, Strausbauch MA, **Lin Y**, Grudem ME, Jatoi A, Klampe CM, Wahner-Hendrickson AE, Weroha SJ, Glaser GE, Kumar A, Langstraat CL, Solseth ML, Deeds MC, Knutson KL, Cannon MJ. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. *Nat Commun.* 2020 Oct 14; 11 (1):5173 PMID: 33057068 PMCID: 7560895 DOI: 10.1038/s41467-020-18962-z
 131. Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, **Lin Y**, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clin Cancer Res.* 2020 Dec 15; 26 (24):6581-6588 Epub 2020 Oct 02 PMID: 33008815 PMCID: 8129639 DOI: 10.1158/1078-0432.CCR-20-2283
 132. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Lust JA, Go RS, **Lin Y**, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, Kumar SK. Prognostic restaging after treatment initiation in patients with AL amyloidosis. *Blood Adv.* 2021 Feb 23; 5 (4):1029-1036 PMID: 33595624 PMCID: 7903228 DOI: 10.1182/bloodadvances.2020003782
 133. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, **Lin Y**, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *N Engl J Med.* 2021 Feb 25; 384 (8):705-716 PMID: 33626253 DOI: 10.1056/NEJMoa2024850
 134. Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, **Lin Y**, Siddiqui M, Go RS, Jevremovic D, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. *Mayo Clin Proc.* 2021 Mar; 96 (3):677-687 PMID: 33673918 PMCID: 7939118 DOI: 10.1016/j.mayocp.2020.06.060
 135. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, **Lin Y**, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. *Blood Cancer J.* 2021 Mar 4; 11 (3):50 Epub 2021 Mar 04 PMID: 33664227 PMCID: 7933343 DOI: 10.1038/s41408-021-00444-0
 136. Drosou ME, Vaughan LE, Muchtar E, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kapoor P, Kourelis T, Kumar S, Kyle RA, Lacy MQ, **Lin Y**, Lopez CL, Lust JA, Rajkumar SV, Russell SJ, Sidana S, Siddiqui MA, Sidiqi MH, Warsame R, Leung N. Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. *Am J Hematol.* 2021 Apr 01; 96(4):446-454. Epub 2021 Jan 28. PMID: 33428787 DOI: 10.1002/ajh.26092
 137. Abeykoon JP, Murray DL, Murray I, Jevremovic D, Otteson GE, Dispenzieri A, Arendt BK, Dasari S, Gertz M, Gonsalves WI, Kourelis TV, Muchtar E, Dingli D, Warsame R, Go RS, Lacy MQ, Leung N, Buadi F, **Lin Y**, Kyle RA, Rajkumar V, Kumar S, Kapoor P. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. *Br J Haematol.* 2021 Apr; 193 (2):380-385 Epub 2020 Nov 20 PMID: 33216966 DOI: 10.1111/bjh.17195
 138. Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, Ghobadi A, **Lin Y**, Lunning M, Lekakis L, Reagan P, Oluwole O, McQuirk J, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose JM, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill BT, Miklos DB. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. *Blood* 2021 Apr 1; 137 (13):1832-1835 PMID: 33156925 PMCID: 8555382 DOI: 10.1182/blood.2020006245
 139. Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves WI, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, **Lin Y**, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy

(mSMART) Consensus Statement 2020 Update. *Mayo Clin Proc.* 2021 Jun; 96(6):1546-1577. PMID: 34088417
DOI: 10.1016/j.mayocp.2021.03.012

140. Jagannath S, **Lin Y**, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N, Anderson LD Jr, Streetly M, Wilson K, Le HV, Swern AS, Agarwal A, Siegel DS. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. *Blood Cancer J.* 2021 Jun 18; 11 (6):116 Epub 2021 June 18 PMID: 34145225 PMCID: 8213772 DOI: 10.1038/s41408-021-00507-2
141. * Melody M, Gandhi S, Rahman ZA, Lengerke-Diaz P, Gannon N, Rosenthal A, Truong T, Novo M, Brandes E, Lange G, Estby B, Johnston P, Ansell S, Bennani NN, Paludo J, Bisneto JV, Ayala E, Tun HW, Murthy HS, Roy V, Foran J, Castro J, **Lin Y**, Kharfan-Dabaja MA. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. *Eur J Haematol.* 2021 Jul; 107 (1):48-53 Epub 2021 Apr 15 PMID: 33655560 DOI: 10.1111/ejh.13609
142. * Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, **Lin Y**. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. *Blood Cancer J* 2021 Jul 1; 11 (7):124 Epub 2021 July 01 PMID: 34210955 PMCID: 8249448 DOI: 10.1038/s41408-021-00515-2
143. Evans LA, Go R, Warsame R, Nandakumar B, Buadi FK, Dispenzieri A, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Kourelis TV, Russell S, Lust JA, **Lin Y**, Siddiqui M, Kyle RA, Gertz MA, Rajkumar SV, Kumar S, Gonsalves WI. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. *Clin Lymphoma Myeloma Leuk.* 2021 Jul; 21 (7):451-460.e2 Epub 2021 Feb 17 PMID: 33785296 PMCID: 8592381 DOI: 10.1016/j.clml.2021.02.001
144. Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, **Lin Y**, Cassaday RD, Park J, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezen R, Wierda WG. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. *Blood.* 2021 Jul 8; 138 (1):11-22 PMID: 33827116 DOI: 10.1182/blood.202009098
145. Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Leung N, Go RS, **Lin Y**, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Broski SM, Rajkumar V, Kumar S. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. *Blood Adv.* 2021 Jul 13; 5 (13):2753-2759 PMID: 34242392 PMCID: 8288674 DOI: 10.1182/bloodadvances.2020004131
146. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schechter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, **Lin Y**, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet.* 2021 Jul 24; 398 (10297):314-324 Epub 2021 June 24 PMID: 34175021 DOI: 10.1016/S0140-6736(21)00933-8
147. Oluwole OO, Bouabdallah K, Munoz J, De Guibert S, Vose JM, Bartlett NL, **Lin Y**, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Kim JJ, Bashir Z, McLeroy J, Zheng Y, Rossi JM, Johnson L, Goyal L, van Meerten T. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. *Br J Haematol.* 2021 Aug; 194 (4):690-700 Epub 2021 July 22 PMID: 34296427 PMCID: 8457222 DOI: 10.1111/bjh.17527
148. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, **Lin Y**, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezen R, Masouleh BK, Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. *Lancet.* 2021 Aug 07; 398(10299):491-502. Epub 2021 Jun 04. PMID: 34097852 DOI: 10.1016/S0140-6736(21)01222-8
149. Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshta KM, **Lin Y**, Ruan J, Porcu P, Brammer JE, Jacobsen ED, Yoon DH, Suh C, Suarez F, Radford J, Budde LE, Kim JS, Bachy E, Lee HJ, Bollard CM, Jaccard A, Kang HJ, Inman S, Murray M, Combs KE, Lee DY, Advani R, Gunter KC, Rooney CM, Heslop HE. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. *Ann Hematol.* 2021 Oct; 100 (10):2529-2539 Epub 2021 July 24 PMID: 34304287 DOI: 10.1007/s00277-021-04558-0
150. Vaxman I, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Kapoor P, Grogan M, Go R, **Lin Y**, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Gertz MA, Dispenzieri A. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. *Leukemia* 2021 Dec; 35 (12):3604-3607 Epub 2021 May 21

PMID: 34021252 PMCID: 8632659 DOI: 10.1038/s41375-021-01297-z

151. Gutierrez C, Brown ART, May HP, Beitinjaneh A, Stephens RS, Rajendram P, Nates JL, Pastores SM, Dharshan A, de Moraes AG, Hensley MK, Feng L, Brudno JN, Athale J, Ghosh M, Kochenderfer JN, Arias AS, **Lin Y**, McEvoy C, Mead E, Westin J, Kostecky N, Mian A, Herr MM. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study. *Crit Care Med*. 2022 Jan 1; 50 (1):81-92 PMID: 34259446 PMCID: 8678137 DOI: 10.1097/CCM.0000000000005149
152. Saifi O, Breen WG, Lester SC, Rule WG, Stish B, Rosenthal A, Munoz J, Herchko SM, Murthy HS, **Lin Y**, Bansal R, Hathcock MA, Bennani NN, Paludo J, Wang Y, Khurana A, Bisneto JCV, Johnston PB, Ansell SM, Iqbal M, Tun H, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? *Radiother Oncol*. 2022 Jan; 166:171-179. Epub 2021 Dec 07. PMID: 34890736 DOI: 10.1016/j.radonc.2021.11.031
153. Audil HY, Cook JM, Greipp PT, Kapoor P, Baughn LB, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Muchtar E, Siddiqui M, Gonsalves WI, Hwa YL, Leung N, **Lin Y**, Kourelis TV, Warsame R, Kyle RA, Ketterling RP, Rajkumar SV, Kumar SK. Prognostic significance of acquired 1q22 gain in multiple myeloma. *Am J Hematol*. 2022 Jan 01; 97(1):52-59. Epub 2021 Nov 03. PMID: 34710241 DOI: 10.1002/ajh.26391
154. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, **Lin Y**, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK. A simple additive staging system for newly diagnosed multiple myeloma. *Blood Cancer J*. 2022 Jan 31; 12 (1):21 PMID: 35102148 PMCID: 8803917 DOI: 10.1038/s41408-022-00611-x
155. * Khurana A, **Lin Y**. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. *Curr Treat Options Oncol*. 2022 Feb; 23 (2):171-187 Epub 2022 Feb 25 PMID: 35212892 PMCID: 8873350 DOI: 10.1007/s11864-021-00920-6
156. Mellors PW, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, **Lin Y**, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Dispenzieri A. Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. *Am J Hematol*. 2022 Feb 1; 97 (2):209-215 Epub 2021 Nov 30 PMID: 34822175 PMCID: 8738145 DOI: 10.1002/ajh.26422
157. Kaddoura M, Binder M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Leung N, Go RS, **Lin Y**, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Rajkumar V, Kumar S. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. *Am J Hematol*. 2022 Mar 01; 97(3):267-273. Epub 2022 Jan 03. PMID: 34978743 DOI: 10.1002/ajh.26439
158. Binder M#, Nandakumar B#, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Gertz MA, Hayman SR, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Gonsalves WI, Russell S, **Lin Y**, Siddiqui M, Kyle RA, Dispenzieri A, Kumar SK. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. *Leukemia*. 2022 Mar; 36(3):801-808. Epub 2021 Oct 26. PMID: 34702976 DOI: 10.1038/s41375-021-01453-5
159. * Breen WG, Hathcock MA, Young JR, Kowalchuk RO, Bansal R, Khurana A, Bennani NN, Paludo J, Villasboas Bisneto JC, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC#, **Lin Y**. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. *J Hematol Oncol* 2022 Mar 26; 15 (1):36 PMID: 35346315 PMCID: 8962609 DOI: 10.1186/s13045-022-01256-w
160. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, **Lin Y**, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. *Nat Med*. 2022 Apr; 28 (4):735-742 Epub 2022 Mar 21 PMID: 35314842 PMCID: 9018426 DOI: 10.1038/s41591-022-01731-4
161. * Abdallah NH, Habermann T, Buadi FK, Gertz MA, Lacy MQ, Rajkumar SV, Dingli D, Go RS, Hayman SR, Kumar SK, Kourelis T, Warsame R, Kapoor P, Muchtar E, Hwa YL, Fonder AL, Hobbs MA, **Lin Y**, Leung N, Binder M, Siddiqui MA, Kyle RA, Witzig TE, Dispenzieri A. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. *Am J Hematol*. 2022 Apr; 97(4):401-410. Epub 2022 Jan 19. PMID: 35015310 DOI: 10.1002/ajh.26466
162. Costa LJ, **Lin Y**, Cornell RF, Martin T, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schechter JM, Kumar S, Hari P. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2022 May; 22(5):326-335. Epub 2021 Oct 30. PMID: 34840088 DOI: 10.1016/j.clml.2021.10.013
163. Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Watson G, Ayers A, Neelapu SS, Khurana A, **Lin Y**, Iqbal M, Merryman RW, Strati P. A multicenter retrospective study of polatuzumab vedotin

- in patients with large B-cell lymphoma after CAR T-cell therapy. *Blood Adv.* 2022 May 10; 6 (9):2757-2762 PMID: 35240681 PMCID: 9092406 DOI: 10.1182/bloodadvances.2021006801
164. Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi F, Hwa L, Leung N, **Lin Y**, Gonsalves WI, Kourelis TV, Warsame R, Fonder A, Hobbs M, Binder M, Kyle RA, Rajkumar SV, Kumar SK. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. *Blood Adv.* 2022 May 10; 6 (9):2763-2772 PMID: 35235951 PMCID: 9092399 DOI: 10.1182/bloodadvances.2022007052
 165. Totzeck M, Michel L, **Lin Y**, Herrmann J, Rassaf T. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. *Eur Heart J.* 2022 May 21; 43 (20):1928-1940 PMID: 35257157 PMCID: 9123242 DOI: 10.1093/eurheartj/ehac106
 166. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, **Lin Y**, Carpenter P, Hamadani M, Usmani S, Kumar S. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. *Transplant Cell Ther.* 2022 Jun; 28 (6):284-293 Epub 2022 Mar 17 PMID: 35306217 DOI: 10.1016/j.jct.2022.03.019
 167. * Melody M, Gandhi S, Saunders H, Abdel-Rahman Z, Hastings J, Lengerke Diaz P, Gannon N, Truong T, Hathcock M, Khurana A, Johnston P, Ansell S, Bennani N, Paludo J, Bisneto JV, Wang Y, Rosenthal A, Foran J, Ayala E, Murthy HS, Roy V, Castro JE, **Lin Y#**, Kharfan-Dabaja MA. Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. *Leuk Lymphoma.* 2022 Jun; 63 (6):1363-1368 Epub 2022 Feb 03 PMID: 35109766 DOI: 10.1080/10428194.2022.2030475
 168. Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schechter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, **Lin Y#**, Jagannath S. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. *J Clin Oncol.* 2022 Jun 4; JCO2200842 Epub 2022 June 04 PMID: 35658469 DOI: 10.1200/JCO.22.00842
 169. * Cook J, Peng KW, Witzig TE, Broski SM, Villasboas JC, Paludo J, Patnaik M, Rajkumar V, Dispenzieri A, Leung N, Buadi F, Bennani N, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton B, Giers M, Ginos B, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, Kumar S, Bergsagel L, Munoz JL, Gonsalves W, Kourelis T, Muchtar E, Kapoor P, Kyle RA, **Lin Y**, Siddiqui M, Fonder A, Hobbs M, Hwa L, Naik S, Russell SJ, Lacy MQ. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. *Blood Adv.* 2022 Jun 14; 6 (11):3268-3279 PMID: 35175355 PMCID: 9198941 DOI: 10.1182/bloodadvances.2021006631
 170. * Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Nevala WK, Walters DK, Parikh SA, **Lin Y**, Jelinek DF, Kay NE, Bergsagel PL, Kenderian SS. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. *Blood.* 2022 Jun 30; 139 (26):3708-3721 PMID: 35090171 DOI: 10.1182/blood.2021012811
 171. * Bansal R, Novo M, Al Saleh AS, Guerrico AG, Zhang H, Shao Z, Babadi E, Martinez KE, McCoy GA, Hathcock MA, Khurana A, Bennani NN, Paludo J, Wang Y, Ansell SM, Johnston PB, Villasboas JC, **Lin Y**. Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. *Am J Hematol* 2022 Jul; 97 (7):E241-E244 Epub 2022 Apr 14 PMID: 35385152 DOI: 10.1002/ajh.26561
 172. * Sidana S, Allmer C, Larson MC, Dueck A, Yost K, Warsame R, Thanarajasingam G, Cerhan JR, Paludo J, Rajkumar SV, Habermann TM, Nowakowski GS, **Lin Y**, Gertz MA, Witzig T, Dispenzieri A, Gonsalves WI, Ansell SM, Thompson CA, Kumar SK. Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. *JCO Oncol Pract.* 2022 Aug; 18 (8):e1320-e1333 Epub 2022 May 17 PMID: 35580285 PMCID: 9377715 DOI: 10.1200/OP.21.00789
 173. Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, **Lin Y**, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. *Transplant Cell Ther.* 2022 Sep; 28 (9):581.e1-581.e8 Epub 2022 May 21 PMID: 35609867 PMCID: 9427701 DOI: 10.1016/j.jct.2022.05.026

Editorials

1. Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, **Lin Y**, Warsame R, Kyle RA, Rajkumar V, Kumar SK. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. *Leukemia* 2023 Jan; 37 (1):1-4

Epub 2022 Dec 08

Commentaries

1. **Lin Y**, Gertz MA. The role of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in aggressive multiple myeloma. *Leuk Lymphoma* 2012 Jun; 53 (6):1021-2 Epub 2012 Jan 31 PMID:22220917 DOI:10.3109/10428194.2011.654340

Abstracts

1. Gustafson M, **Lin Y**, Maas M, Bulur P, Gastineau D, Dietz A. Classifying patients and monitoring the outcomes of cell based therapies using immunomics. *Cytotherapy*. 2014 Apr; 16(4):S15-6.
2. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, **Lin Y**, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK. Kinetics of organ response and survival following normalization of the serum free light chain ratio in al amyloidosis. *Haematologica*. 2014 Jun 1; 99:794-5.
3. **Lin Y**, Atwell T, Weisbrod A, Maas M, Armstrong AS, Deeds M, Bulur PA, Gustafson M, Zhang Z, Cordes S, Porrata LF, Markovic SN, Johnston PB, Micallef IN, Inwards DJ, Colgan JP, Ansell SM, Gastineau DA, Dietz AB, Witzig TE. Dendritic cell vaccine treatment for b-cell non-Hodgkin lymphoma: clinical trial in progress. *Blood*. 2014 Dec 6; 124(21).
4. Hwa YL, Lacy MQ, Gertz MA, Buadi F, Rajkumar SV, Kumar S, Kapoor P, Go RS, Hayman SR, **Lin Y**, Lust JA, Dingli D, Russell SJ, Gonsalves WI, Dispenzieri A. Impact of beta blocker on clinical outcomes of multiple myeloma (mm) patients. *Blood*. 2014 Dec 6; 124(21):4751.
5. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Buadi F, Lacy MQ, Dingli D, Kapoor P, Go RS, Lust JA, Hayman SR, **Lin Y**, Zeldenrust SR, Kyle RA, Gertz MA, Kumar S. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. *Blood*. 2014 Dec 6; 124(21).
6. Zhang Z, Bulur PA, Gustafson M, Gastineau DA, Dietz AB, **Lin Y**. Lymphoma monocyte crosstalk via hsp27 to promote immune suppression and chemotherapy resistance. *Blood*. 2014 Dec 6; 124(21).
7. Zhang HN, Braggio E, Davila J, Feldman AL, Call TG, Witzig TE, **Lin Y**, Secreto C, Patnaik MM, Cerhan JR, Parikh SA, Baheti S, Ding W. Novel phenotypic and genetic analysis of t-cell prolymphocytic leukemia (t-pll). *Blood*. 2014 Dec 6; 124(21).
8. Kourelis T, Kyle RA, Kumar S, Gertz MA, Lacy M, Kapoor P, Buadi F, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, **Lin Y**, Leung N, Dispenzieri A. Outcomes and treatment of patients with poeems syndrome experiencing progression or relapse after first line treatment. *J Clin Oncol*. 2015 May 20; 33(15).
9. Gonsalves WI, Rajkumar V, Morice W, Timm M, Dispenzieri A, Buadi F, Lacy M, **Lin Y**, Dingli D, Hayman SR, Zeldenrust SR, Russell SJ, Leung N, Kapoor P, Gertz MA, Kumar S. The prognostic significance of cd45 expression by clonal bone marrow plasma cells in multiple myeloma. *J Clin Oncol*. 2015 May 20; 33(15).
10. Thompson C, Towns J, Dripps L, Jenkins S, Lackore K, Yost K, Ristow K, Colgan J, Habermann T, Inwards D, Johnston P, Klebig R, **Lin Y**, Markovic S, Micallef I, Nowakowski G, Porrata L, Rosenthal A, Witzig T, Ansell S. Impact of lymphoma survivorship clinic visit on patient-centered outcomes *J Clin Oncol*. 2016; 34(Suppl 3S). Abstract no. 64.
11. Ding W, Le-Rademacher J, Call TG, Parikh SA, Leis JF, Shanafelt TD, He R, Habermann TM, **Lin Y**, Laplant BR, Feldman AL, Witzig TE, Chanan-Khan AA, Asmus A, Van DL, Conte MJ, Bowen DA, Sinha S, Zhang H, Liu X, Secreto CR, Tian S, Braggio E, Micallef I, Yan H, Kay NE, Dong H, and SM. PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). *Blood*.2016;128:(22)4392.
12. Zanwar S, Abeykoon JP, Ansell SM, King RL, He R, Gertz MA, Greipp PT, Kyle RA, Habermann TM, Dingli D, Novak A, Inwards DJ, Buadi FK, Nowakowski GS, Thompson CA, Johnston PB, Thanarajasingam G, Bennani NN, Witzig TE, Micallef IN, Porrata LF, Villasboas JC, Dispenzieri A, Lacy MQ, Go RS, Muchtar E, Kourelis T, Gonsalves WI, **Lin Y**, Rajkumar S, Kumar SK, Kapoor P. Impact of MYD88(L265P) mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia *Blood*. 2018; 132(Suppl 1):2884.
13. Binder M, Nandakumar B, Gertz MA, Dispenzieri A, Lacy MQ, Maurer MJ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Hwa YL, Fonder A, Hobbs MA, **Lin Y**, Leung N, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Mortality of patients with multiple myeloma after the introduction of novel therapies in the United States. *Blood*. 2019; 134(Suppl 1):72.
14. **Lin Y**, Martin T III, Cohen AD, Jakubowiak A, Jasielc J, Usmani SZ, Madduri D, Agha M, Stewart AK, Singh I, Zudaire E, Yeh T, Allred AJ, Olyslager Y, Banerjee A, Goldberg JD, Schechter JM, Jackson CC, Deraedt W, Geng D, Wu X, Carrasco MJ , Akram M, Hossain F, Wang V, Berdega JG, Jagganath S. Cytokine Release

Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucl in the Phase 1b/2 CARTITUDE-1 Study Blood. 2020; 136(Supplement 1):45-46.

15. Berdeja JG, Raje NS, Siegel DS, **Lin Y**, Anderson LD, Rodriguez-Otero P, Manier S, Einsele H, Cavo M, Truppel-Hartmann A, Rowe E, Sanford J, Wang J, Campbell TB, Jagannath S. Efficacy and Safety of Idecabtagene Vicleucl (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis Blood. 2020; 136(Supplement 1):16-17.
16. Thomas M, **Lin Y**, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, Madduri D, Usmani SZ, Yeh T, Allred AJ, Olyslager Y, Banerjee A, Goldberg JD, Schechter JM, Jackson CC, Deraedt W, Gries KS, Fastenau J, Wu X, Carrasco MJ, Akram M, Hossain F, Jakubowiak A, Jagannath S. Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucl for Relapsed/Refractory Multiple Myeloma Blood. 2020; 136(Supplement 1):41-42.
17. * Arushi Khurana, Abdullah S. Al Saleh, Sangeetha Gandhi, Tuan A Truong, Nabila Bennani, Jonas Paludo, Jose C Villasboas, Patrick B. Johnston, Stephen M. Ansell, **Yi Lin**. Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL) Blood. November 5 2020; 136((Supplement 1)):30.
18. Barreto JN, Doleski CJ, Hayne JR, Hathcock MA, Truong TA, Ansell SM, Bennani NN, Paludo J, Villasboas J, **Lin Y**, Johnston PB. The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Blood. 2020; 136(Supplement 1):23-25.
19. May H, Herr M, Gutierrez C, Brown AR, Rajendram P, Hill B, Duggal A, **Lin Y**, Gallo De Moraes A, Feng L, Dharshan A, Arias S, Mead E, Nates J, Pastores S, Ghosh M, Hensley M, Westin J, Beitinjaneh A. Cytokine release syndrome in chimeric antigen receptor t-cell therapy: the car-icu experience Critical Care Medicine. 2021 Jan; 49(1 Suppl):23
20. Brown AR, Rajendram P, Herr MM, Hill B, **Lin Y**, Duggal A, May HP, Arias AS, Gallo De Moraes A, Feng L, Dharshan A, Beitinjaneh A, Pastores S, Ghosh M, Nates JL, Hensley M, Mead E. Chimeric Antigen Receptor (CAR) Cell Patients Admitted to the ICU: The CAR-ICU Initiative Experience Critical Care Medicine. 2021; 49(S1):483. Abstract no. 4508.
21. Hensley MK, Ghosh M, Herr MM, Dharshan AC, Rajendram P, Hill B, Duggal A, **Lin Y**, May HP, Gallo De Moraes A, Feng L, Beitinjaneh A, Arias AS, Nates JL, Westin J, Mead E, Pastores SM. Neurotoxicity in Critically ill Chimeric Antigen Receptor (CAR) Patients: The CAR-ICU Experience Critical Care Medicine. 2021; 49(S1):482. Abstract no. 4506.
22. Khurana ,, Hathcock Matthew, Habermann Thomas, Al Abdullah, Gandhi Sangeetha, Truong Tuang, Bennani N, Paludo Jonas, Villasboas Jose, Ansell Stephen, Inwards David, Porrata Luis, Johnston Patrick, Micallef Ivana, **Lin Yi**. Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL) Abstract presented at Transplantation & Cellular Therapy Meetings. 2/09/2021.
23. Manier S, Kansagra AJ, Anderson LD Jr., Berdeja JG, Jagannath S, **Lin Y**, Lonial S, Shah N, Raje NS, DiCapua Siegel DS, Oriol A, Truppel-Hartman n A, Rowe E, Patel P, Agarwal A, Campbell TB, Rodriguez-Otero P, Munshi NC, KarMMa Study Investigators on behalf of the. Characteristics of neurotoxicity associated with idecabtagene vicleucl (ide-cel bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study. Journal of Clinical Oncology. 2021; 39(Supplement 15):8036. Abstract no. 8036. Epub 2021 May 28.
24. Usmani SZ, Berdeja JG, Madduri D, Jakubowiak AJ, Agha ME, Cohen AD, Hari P, Yeh T, Olyslager Y, Banerjee A, Jackson CC, Allred AJ, Zudaire E, Deraedt W, Wu X, Carrasco-Alfonso M, Akram M, **Lin Y**, Martin TG, Jagannath S. Ciltacabtagene autoleucl, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. Journal of Clinical Oncology. 2021; 39(Supplement 15):8005. Abstract no. 8005. Epub 2021 May 28.
25. Costa LJ, **Lin Y**, Martin TG, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schechter JM, Kumar SK, Hari P. Cilta-cel versus conventional treatments in patients with relapse/refractory multiple myeloma. Journal of Clinical Oncology. 2021; 39(Supplement 15):8030. Abstract no. 8030. Epub 2021 May 28.
26. Anderson LD, Munshi NC, Shah N, Jagannath S, Berdeja JG, Lonial S, Raje NS, DiCapua Siegel DS, **Lin Y**, Oriol A, Moreau P, Yakoab-Agha I, Delforge M, Petrocca F, Patel P, Huang L, Campbell TB, Hege K, San-Miguel JF, KarMMa Study Investigators on behalf of the. Idecabtagene vicleucl (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. Journal of Clinical Oncology. 2021; 39(Supplement 15):8016. Abstract no. 8016. Epub 2021 May 28.
27. Evans LJ, Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Go RS, Buadi F, Leung N, **Lin Y**, Hayman SR, Russell

- SJ, Muchtar E, Kapoor P, Siddiqui MA, Warsame R, Kourelis T, Kyle RA, Gertz MA, Rajkumar S, Gonsalves WI. Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM). *Journal of Clinical Oncology*. 2021; 39(Supplement 15). Abstract no. e20016. Epub 2021 May 28.
28. Shah BD, Ghobadi A, Oluwole OO, Logan A, Boissel N, Cassaday RD, Forcade E, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, **Lin Y**, Baer MR, Schiller GJ, Dong J, Shen T, Milletti F, Masouleh BK, Houot R. Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) *Journal of Clinical Oncology*. 2021; 39(Supplement 15):7002. Abstract no. 7002. Epub 2021 May 28.
 29. Jacobson CA, Locke FL, Hu Z, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, **Lin Y**, Perales MA, Lunning MA, Herr M, Hill BT, Ganguly S, Dong H, Nikiforow S, Xie J, Xu H, Hooper M, Kawashima J, Pasquini MC. Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US). *Journal of Clinical Oncology*. 2021; 39(15 Supplement). Abstract no. 7552. Epub 2021 May 28.
 30. Andrade-Gonzalez X, Saliba A, Fuentes-Bayne HE, Xie Z, Habermann TM, Villasboas Bisneto J, Paludo J, Thanarajasingam G, Thompson CA, **Lin Y**, Bennani NN, Johnston PB, Micallef IN, Porrata L, Inwards DJ, Witzig TE, Ansell SM, Nowakowski SE, Wang Y. Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis. *Journal of Clinical Oncology*. 2021; 39(Supplement 15):7542. Abstract no. 7542. Epub 2021 May 28.
 31. Wudhikarn K, Bansal R, Khurana A, Hathcock M, Ruff M, Carabenciov ID, Braksick SA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, **Lin Y**. Characteristics, Outcomes, and Risk Factors of ICANS After Axicabtagene: Does Age Matter? *J Clin Oncol*. 2021; 39(15). Abstract no. e19556.
 32. McLaughlin NR, Wang Y, Inwards DJ, Villasboas Bisneto J, Micallef IN, Habermann TM, Nowakowski GS, Witzig TE, Thanarajasingam G, Porrata L, **Lin Y**, Thompson CA, Bennani NN, Johnston PB, Ansell SM, Paludo J. Outcomes in mantle cell lymphoma with central nervous system involvement. *Journal of Clinical Oncology*. 2021; 39(15). Abstract no. e19527.
 33. Bansal R, Vergidis P, Tosh P, Wilson JW, Hathcock M, Bennani NN, Paludo J, Villasboas JC, Wang Y, Ansell SM, Johnston PM, Freeman CM, **Lin Y**. Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy *American Society of Clinical Oncology (ASCO)*. 2021.
 34. Bansal , R., Paludo , J., Holland , A., Spychalla , M., Alli , M., Hathcock , M., Alkhateeb , H., Wang , Y., Kenderian , S., Kumar , S., Shah , M.V., Mustaqeem , S., Warsame , R.M., Villasboas , J.C., Bennani , N.N., Johnston , P.B., Ansell , S.M., Haddad , TC, **Lin , Y**. Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma. *J Clin Oncol*. 2021; 39(supple 15). Abstract no. 7554.
 35. Bansal R, Zhang H, Martinez K, Hathcock M, Shao Z, McCoy G, Gonzalez Guerrico A, Bennani N, Paludo J, Wang Y, Patrick J, Stephen A, Kenderian S, Porrata L, Villasboas Bisneto J, **Lin Y**. Prognostic role of lymphocyte to monocyte ratio in pts treated with car-t for aggressive lymphoma *Clinical Lymphoma Myeloma & Leukemia*. 2021 Sep; 21:S453
 36. Cook J, Peng K, Witzig TE, Broski SM, Villasboas Bisneto J, Paludo J, Patnaik M, Rajkumar S, Dispenzieri A, Leung N, Buadi F, Bennani NN, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton BA, Giers MJ, Ginos BF, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, Kumar SK, Bergsagel P, Gonsalves WI, Kourelis T, Muchtar E, Kapoor P, Kyle RA, **Lin Y**, Siddiqui MA, Fonder AL, Hobbs MA, Hwa YL, Russell SJ, Lacy MQ. An Analysis of Virtus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β -NIS) *Blood*. 2021; 138(Supplement 1):1333.
 37. Bezerra E, Munoz J, Murthy H, Khurana A, Bansal R, Iqbal M, Maurer M, Hathcock MA, Johnston PB, Bennani NN, Paludo J, Wang Y, Villasboas Bisneto J, Rosenthal AC, Ansell SM, Witzig TE, Castro JE, Kharfan Dabaja M, Nowakowski GS, **Lin Y**. Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy *Blood*. 2021; 138(Supplement 1):2527.
 38. Khurana A, Bansal R, Hathcock MA, Nedved AN, Wang Y, Paludo J, Villasboas Bisneto J, Bennani NN, Johnston PB, Ansell SM, **Lin Y**. Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience *Blood*. 2021; 138(Supplement 1):3842.
 39. Wong SW, Richard S, **Lin Y**, Madduri D, Jackson CC, Zudaire E, Romanov V, Trigg M, Vogel M, Garrett A, Hullinger L, Nesheiwat T, Martin T, Jagannath S. Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor-Cell Therapies *Blood*. 2021; 138(Supplement 1):2812. Epub 2021 Nov 05.
 40. Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, Frank MJ, Dahiya S, McGuirk JP, Jacobs MT,

- Goy AH, Vose JM, Hill BT, Oluwole OO, Deol A, Shah BD, Paludo J, Wang T, Lekakis LJ, Miklos DB, Rapoport AP, Ghobadi A, Neelapu SS, **Lin Y**, Wang M, Jain MD. Brexucabtagene Autoleucl for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium Blood. 2021; 138(Supplement 1):744. Epub 2021 Nov 05.
41. Kaddoura M, Binder M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Go R, **Lin Y**, Gonsalves WI, Kourelis T, Warsame RM, Kyle RA, Rajkumar SV, Kumar SK. Impact of achieving an early complete response in multiple myeloma and predictors of subsequent outcome. Blood. 2021; 138(Suppl 1):3773.
 42. Breen W, Young JR, Hathcock M, Kowalchuk RO, Bansal R, Khurana A, Bennani NN, Paludo J, Villasboas JC, Wang Y, Ansell SM, Peterson J, Johnston PB, Lester S, **Lin Y**. Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucl CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity Blood. 2021; 138 (Supplement 1):2518.
 43. Binder M, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Gertz MA, Hayman SR, Leung N, Fonder A, Hobbs MA, Hwa YL, Muchtar E, Warsame RM, Kourelis T, Gonsalves WI, Russell SJ, **Lin Y**, Siddiqui MA, Kyle RA, Dispenzieri A, Kumar SK. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Blood. 2021; 138(Suppl 1):119.
 44. Bansal R, Gonzalez Guerrico AM, Zhang H, Shao Z, Babadi E, Martinez KE, Gonzalez McCoy G, Hathcock MA, Khurana A, Bennani NN, Paludo J, Wang Y, Ansell SM, Johnston PB, Villasboas Bisneto J, **Lin Y**. Peak Absolute Lymphocyte Count Post CAR-T Is Associated with Clinical Response and Survival outcome in Aggressive Lymphoma Blood. 2021; 138(Supplement 1):3856. Epub 2021 Nov 05.
 45. Paludo J, Bansal R, Holland AT, Haugen KL, Spychalla MT, McClanahan AL, Truong TA, Hathcock MA, Khurana A, Alkhateeb H, Dingli D, Hayman SR, Kapoor P, Gertz MA, Wang Y, Kenderian S, Kourelis T, Kumar SK, Shah M, Siddiqui MA, Warsame R, Villasboas J, Bennani NN, Johnston PB, Ansell SM, Haddad TC, **Lin Y**. Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy Blood. 2021; 138(Supplement 1):568. Epub 2021 Nov 05.
 46. Warsame RM, Gertz MA, Buadi FK, Go R, Kumar SK, Dingli D, Kyle RA, Leung N, Kourelis T, Hayman SR, **Lin Y**, Lacy MQ, Lust JA, Hwa YL, Fonder A, Kapoor P, Hobbs MA, Gonsalves WI, Rajkumar SV, Muchtar E, Visram A, Russell SJ, Dispenzieri A. Prognostic role of IL-6 in POEMS syndrome. Blood. 2021; 138(Suppl 1):2700.
 47. Khurana A, Hathcock MA, Bansal R, Wang Y, Paludo J, Villasboas Bisneto J, Bennani NN, Johnston PB, Ansell SM, **Lin Y**. Response to Bridging Therapy As a Predictor of Outcomes for Chimeric Antigen Receptor Therapy in Large B-Cell Lymphoma Blood. 2021; 138(Supplement 1):3841. Epub 2021 Nov 05.
 48. Wiedmeier-Nutor JE, Iqbal M, Munoz J, Bezerra E, Garcia Robledo JE, Bansal R, Johnston PB, Hathcock MA, Larsen JT, Bergsagel P, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Warsame R, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas Bisneto J, Paludo J, Bennani NN, Ansell SM, Castro JE, Kharfan Dabaja M, **Lin Y**, Vergidis P, Murthy H, Rosenthal AC. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Blood. 2021; 138(Supplement 1):1750. Epub 2021 Nov 05.
 49. Kumar SK, Jessen E, Dispenzieri A, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Leung N, Muchtar E, Warsame RM, Kourelis T, Russell SJ, **Lin Y**, Siddiqui MA, Jang JS, Kyle RA, Rajkumar SV, Gertz MA, Fonseca R, Gonsalves WI. The impact of the central carbon energy metabolism transcriptome in the pathogenesis and outcomes of multiple myeloma. Blood. 2021; 138(Suppl 1):2650.
 50. Asmann Y, **Li Y**, Kourelis T, Binder M, Gonsalves WI, Zhang H, Gonzalez Guerrico A, Shao Z, Kapoor P, Dingli D, Warsame RM, Dong H, Kumar SK, **Lin Y**. Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART Blood. 2021.
 51. Asmann Y, **Li Y**, Kourelis T, Binder M, Gonsalves WI, Zhang H, Gonzalez Guerrico A, Shao Z, Kapoor P, Dingli D, Warsame RM, Dong H, Kumar SK, **Lin Y**. Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART Blood. 2021.
 52. B. Dasgupta, Unizony S., Warrington KJ, Lazar J. Sloane, Giannelou A., Nivens C., Akinlade B., Wong W., **Lin Y.**, Buttgerit F., Devauchelle-Pensec V., Rubbert-Roth A., Spiera R.. SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (SAPHYR) Annals of the Rheumatic Diseases. June 2022; Volume 81(Supplement 1):abstract 210. Abstract no. LB0006.
 53. Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal AC, Munoz J, **Lin Y**, Bennani NN, Paludo J, Khurana A, Villasboas Bisneto J, Johnston P, Ansell SM, Iqbal M, Alhaj Moustafa M, Kharfan Dabaja M, Murthy H, Hoppe B, Peterson J. In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART) Journal of Clinical

Oncology. 2022.

Letters

1. Gustafson MP, Abraham RS, **Lin Y**, Wu W, Gastineau DA, Zent CS, Dietz AB. Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). *Br J Haematol*. 2012 Mar; 156(5):674-6. Epub 2011 Nov 3 PMID:22050346 DOI:10.1111/j.1365-2141.2011.08902.x
2. * Novo M, Ruff MW, Skrabek PJ, **Lin Y**. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. *Mayo Clin Proc* 2019 Nov; 94 (11):2361-2364 PMID:31685159 DOI:10.1016/j.mayocp.2019.09.006
3. Ruan G, Zanwar S, Abeykoon JP, Ansell SM, Gertz M, Go RS, Muchtar E, Gonsalves WI, Paludo J, Thanarajasingam G, Inwards DJ, Thompson CA, Habermann TM, **Lin Y**, Nowakowski GS, Bisneto JCV, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Kourelis T, Warsame R, Rajkumar SV, Kumar S, Kapoor P. Predictors of short-term survival in Waldenström Macroglobulinemia. *Leuk Lymphoma*. 2020 Dec; 61(12):2975-2979. Epub 2020 Jul 14. PMID:32662697 DOI:10.1080/10428194.2020.1789625
4. * Khurana A, Hathcock M, Habermann TM, Al Saleh AS, Gandhi S, Truong T, Bennani NN, Paludo J, Villasboas JC, Ansell SM, Inwards DJ, Porrata LF, Johnston PB, Micallef I, **Lin Y**. Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin's lymphoma. *Am J Hematol*. 2021 Oct 01; 96(10):E386-E389. Epub 2021 Jul 29. PMID:34260759 DOI:10.1002/ajh.26293
5. * Saw JL, Sidiqi MH, Ruff M, Hocker S, Alkhateeb H, Ansell SM, Bennani NN, Dingli D, Hayman SR, Johnston PB, Kapoor P, Kenderian SJ, Kourelis TV, Kumar SK, Paludo J, Shah MV, Siddiqui MA, Warsame R, Rosenthal A, Grill M, Castro JE, Siegel J, Abdel Rahman ZH, Kharfan-Dabaja MA, So E, **Lin Y**. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). *Blood Cancer J*. 2022 Apr 13; 12(4):62. PMID:35418113 DOI:10.1038/s41408-022-00657-x
6. Acosta-Medina AA, Johnson IM, Bansal R, Hathcock M, Kenderian SJ, Durani U, Khurana A, Wang Y, Paludo J, Villasboas JC, Bennani NN, Johnston PB, Ansell SM, **Lin Y**, Alkhateeb HB. Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. *Blood Cancer J* 2023 Jan 5; 13 (1):7 Epub 2023 Jan 05 PMID:36599834 DOI:10.1038/s41408-022-00777-4
7. Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, **Lin Y**, Warsame RM, Kyle RA, Rajkumar SV, Kumar SK. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. *Blood Cancer J* 2023 Jan 11; 13 (1):11 PMID:36631454 DOI:10.1038/s41408-023-00785-y

Miscellaneous

1. **Lin Y**, Gertz MA. The role of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in aggressive multiple myeloma. *Leuk Lymphoma*. 2012 Jun; 53(6):1021-2.
2. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, **Lin Y**, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. *Nat Rev Clin Oncol*. 2018 Apr; 15(4):218.

* Indicates the primary author was a mentee of this author.

Indicates the authors contributed equally.

RE-AIMS 2/1/2023 9:43:45 PM - Latest Update 2/1/2023 8:17:28 PM